




US 20100146642A1

(19) **United States**(12) **Patent Application Publication**
Shi et al.(10) **Pub. No.: US 2010/0146642 A1**(43) **Pub. Date: Jun. 10, 2010**(54) **METHODS AND COMPOSITIONS RELATING
TO PBK1**(75) Inventors: **Yuguang Shi**, Hershey, PA (US);
Guangming Ye, Hershey, PA (US)

Correspondence Address:

**GIFFORD, KRASS, SPRINKLE, ANDERSON &
CITKOWSKI, P.C**
PO BOX 7021
TROY, MI 48007-7021 (US)(73) Assignee: **The Pennsylvania State
University**, University Park, PA
(US)(21) Appl. No.: **12/154,296**(22) Filed: **May 22, 2008****Related U.S. Application Data**(60) Provisional application No. 60/939,462, filed on May
22, 2007.**Publication Classification**(51) **Int. Cl.**
A61K 49/00 (2006.01)
G01N 33/567 (2006.01)
C12N 5/071 (2010.01)
G01N 33/53 (2006.01)
C12N 9/12 (2006.01)
A61P 3/10 (2006.01)
(52) **U.S. Cl. 800/3; 435/7.21; 435/325; 435/7.2;
435/194**(57) **ABSTRACT**

The invention relates to compositions comprising, and methods utilizing PBK1 protein and DNA, including a method of detecting type 1 diabetes; a mammalian pancreas-derived cell comprising a recombinant nucleic acid encoding a PBK1 protein; a method of identifying a PBK1 modulator; a pharmaceutical composition for treatment of type 2 diabetes in a subject; a method of screening for an agent that treats a metabolic disease; delivery of PBK-1 DNA to a subject to stimulate pancreatic beta cell differentiation and/or regeneration; a method for stimulating cell differentiation and/or regeneration in a pancreatic beta cell; usage of transgenic mice with targeted deletion or overexpression of the PBK-1 gene to test efficacy and specificity of PBK-1 modulator compounds.






FIG. 1A




FIG. 1B




FIG. 1C

Western Blot Analysis of PBK1 Expression in Mouse Pancreas




Figure 2


200 

FIG. 2A




FIG. 2B




Figure 3

300




FIG. 3A





FIG. 3B



FIG. 3C



400




FIG. 4





Figure 4






FIG. 5B1




FIG. 5B2




FIG. 5C1




FIG. 5C2




FIG. 5D




FIG. 5E




FIG. 5F




FIG. 5G




FIG. 5H



FIG. 5I




FIG. 5J




FIG. 5K




FIG. 5L




FIG. 5M




FIG. 5N




FIG. 5O




FIG. 5P

Subcellular Localization of PBK-1 Overexpressed in Min6 Cells







Figure 6








FIG. 7D




FIG. 7E




FIG. 7F




FIG. 7G




FIG. 7H

750




FIG. 7I




FIG. 7J

METHODS AND COMPOSITIONS RELATING TO PBK1

[0001] This application claims the benefit of priority from U.S. provisional application 60/939,462, filed May 22, 2007, the entire contents of which is hereby incorporated herein by reference.

REFERENCE TO SEQUENCE LISTING APPENDIX

[0002] Amino acid and nucleic acid sequences are shown in appended pages marked "Appendix" and are also being submitted on the accompanying compact disc; said amino acid and nucleic acid sequences are considered part of this application and are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

[0003] The invention relates to compositions comprising, and methods utilizing PBK1 protein and DNA.

BACKGROUND OF THE INVENTION

[0004] It was estimated that approximately 150 million people worldwide had type 2 diabetes (T2D) in the year 2000, with the prediction that this number could double to 300 million by 2025 (1). T2D is characterized by insulin resistance in peripheral tissues and deficient β -cell insulin-secretory response to glucose. Glucose-sensing by pancreatic β -cell plays an important role in regulating glucose homeostasis and onset of T2D. Normal pancreatic β -cells are able to sense minor changes in blood glucose levels, and promptly respond to such changes by adjusting insulin secretion rates to maintain normoglycemia (2). In patients with insulin resistance, the pancreatic β -cells have to secrete higher levels of insulin as a compensatory response to insulin resistance in order to maintain normoglycemia, resulting in hyperinsulinemia. Consequently, T2D develops only in subjects that are unable to sustain this β -cell compensatory response (3, 4). This is supported by results from longitudinal studies of subjects that develop T2D. These patients show a rise in insulin levels in the normoglycemic and prediabetes phases, followed by a decline in insulin secretion when β cells lose their ability to sense glucose, resulting pancreatic β cell failure and onset of diabetes (5). A longitudinal study in Pima Indians also confirmed that β -cell dysfunction was the major determinant of progression from normoglycemia to diabetes (6). Furthermore, the natural history of T2D entails progressive deterioration in β -cell function (7) and loss of β cell mass due to apoptosis (8, 9).

[0005] Current treatment options for type 2 diabetes include insulin, sulfonylureas, glitinides, acarbose, metformin, thiazolidinediones. These drugs lower blood glucose through diverse mechanisms of action. However, many of the drugs cannot prevent β -cell death or re-establish β -cell mass, and most of the oral hypoglycemic agents lose their efficacy over time, resulting in progressive deterioration in β -cell function and loss of glycemic control. Moreover, sulfonylurea therapy has been shown to induce apoptosis in rodent β -cells (10) or cultured human islets (11), thus likely exacerbating β -cell loss in T2D patients. Consequently, there has been intense interest in the development of therapeutic agents that preserve or restore functional β -cell mass (12). Several

agents with the potential to inhibit β -cell apoptosis and/or increase β -cell mass have been identified in preclinical studies (12). One of the agents, a GLP-1 analogue, commercially known as Byetta (exenatide), has been shown to lower blood glucose level by improving β -cell function (β -15). Byetta is a peptide derived from the venom of the Gila monster, a poisonous lizard. Treatment of β -cell with Byetta has been shown to improve β -cell glucose sensing concurrent with preservation of β -cell mass and stimulation of β -cell regeneration (16). However, Byetta must be administered by injection twice daily, and long term usage of the drug has been associated with development of anti-exenatide antibodies in diabetic subjects. Additionally, the drug slows gastric emptying, and causes gastrointestinal discomfort.

[0006] Thus, there is a continuing need for compositions and methods for detection and treatment of diabetes in a subject. Further, development, of an oral antidiabetic drug that can improve glucose sensing by pancreatic β -cells is required for treatment of type 2 diabetes.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] FIG. 1 depicts a northern blot that indicates that PBK1 mRNA is most abundantly expressed in human pancreas.

[0008] FIG. 2 depicts a western blot that indicates that PBK1 is predominantly expressed in endocrine islets, and that PBK1 protein expression was significantly up-regulated in islets of diabetic db mice.

[0009] FIG. 3 graphically represents insulin levels at indicated glucose concentrations for Min-6 cells comprising vector, PBK1, a dominant negative mutant of PBK1 (DN), and a PKA phosphorylation defective mutant of PBK1 (T260A); demonstrating that PBK1 overexpression improved glucose-sensing by Min-6 cells.

[0010] FIG. 4 depicts RT-PCR and insulin secretion data related to inhibition of PBK1 and PBK2 mRNA expression.

[0011] FIG. 5 graphically represents a time course for oral glucose tolerance in PBK1 heterozygous knockout mice and wild type controls.

[0012] FIG. 6 depicts western blot data related to subcellular localization of recombinant PBK1.

SUMMARY OF THE INVENTION

[0013] The invention relates to compositions comprising, and methods utilizing PBK1 protein and DNA.

[0014] In one aspect, the invention provides a method of detecting type 1 diabetes in a patient, comprising: reacting a patient sample with a PBK1 protein or a fragment thereof under conditions that promote antibody-antigen binding; and detecting the presence of an autoantibody in said sample.

[0015] In one embodiment of the present invention, the PBK1 protein is immobilized on a solid support. In another embodiment, the patient sample is selected from the group consisting of: blood, serum, plasma, and a biopsy tissue. In another, the detecting of the autoantibody comprises reacting the autoantibody with an antibody having a detectable label.

[0016] In another aspect, the invention provides a mammalian pancreas-derived cell comprising a recombinant nucleic acid encoding a PBK1 protein.

[0017] In one embodiment of the present invention, the cell is a cell of a mammalian pancreas-derived cell line. In another embodiment, the cell is a Min6 cell transfected with a recombinant nucleic acid encoding a PBK1 protein.

[0018] In another aspect, the invention provides a method of detecting a PBK1 modulator, comprising: contacting PBK1 with a compound; and detecting a change in PBK1 activity, the change in PBK1 activity indicative that the compound is a PBK1 modulator.

[0019] In a related aspect, the invention encompasses a pharmaceutical composition for treatment of type 2 diabetes in a subject, the composition comprising a modulator of PBK1.

[0020] In a further related aspect, the invention provides a method of identifying a PBK1 modulator, comprising one or more of: a) contacting a PBK1 protein with a test agent under conditions that promote kinase activity of said PBK1 protein, and detecting an increase in the kinase activity; and b) contacting a cell that expresses a PBK1 protein with a test agent under conditions that promote glucose-stimulated insulin secretion from said cell, and detecting an increase in the glucose-stimulated insulin secretion from the cell; wherein said increase in a) or b) each indicates that the test agent is a PBK1 modulator.

[0021] In one embodiment of the present invention, the method further comprises determining that the increase in the glucose-stimulated insulin secretion comprises potentiation of secretagogue-stimulated insulin secretion from a cell that expresses a PBK1 protein. In another embodiment, the cell is a mammalian pancreas-derived cell. In another, the cell is a MIN6 cell. In another, the cell contains a recombinant nucleic acid encoding a PBK1 protein.

[0022] In another aspect, the invention provides a method of screening for an agent that treats a metabolic disease, said method comprising one or more of:

[0023] a) contacting a PBK1 protein with a test agent under conditions that promote binding of said test agent to said PBK1 protein, and detecting binding of said test agent to said PBK protein;

[0024] b) contacting a PBK1 protein with a test agent under conditions that promote kinase activity of said PBK1 protein, and detecting an increase in the kinase activity; and

[0025] c) contacting a cell that expresses a PBK protein with a test agent under conditions that promote glucose-stimulated insulin secretion from said cell, and detecting an increase in the glucose-stimulated insulin secretion from the cell; wherein said disorder is selected from diabetes, type 2 diabetes, obesity, and diabetic retinopathy.

[0026] In one embodiment of the present invention, the screening method further comprises designating said test agent as an agent that treats said disease. In another embodiment, the screening method further comprises designating said test agent as an agent that treats type 2 diabetes.

[0027] In another embodiment, the PBK1 protein is selected from a protein having a polypeptide sequence that has at least 73%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the protein having a polypeptide sequence set forth in SEQ ID NO: 2.

[0028] In another embodiment, the PBK1 protein is selected from a protein having a polypeptide sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 6.

[0029] In another embodiment, step a) is performed prior to step c). In another, step b) is performed prior to step c). In another, step a) is performed prior to b), and step b) is performed prior to step c).

[0030] In another embodiment, the screening method further comprises determining that the increase in the glucose-stimulated insulin secretion comprises potentiation of secre-

tagogue-stimulated insulin secretion from a cell that expresses a PBK1 protein. In another, the cell is a mammalian pancreas-derived cell. In another, the cell is a MTN6 cell. In another, the cell contains a recombinant nucleic acid encoding a PBK1 protein.

[0031] In another aspect, the invention comprehends delivery of PBK-1 DNA to a subject to stimulate pancreatic beta cell differentiation and/or regeneration.

[0032] In a related aspect, the invention provides a method for stimulating cell differentiation and/or regeneration in a pancreatic beta cell comprising delivering PBK-1 DNA to said cell. In one embodiment of the present invention, the DNA is operably linked to a promoter that drives expression of said DNA in said cell. In one embodiment, the promoter is an adenoviral promoter, retroviral promoter, or any promoter that can direct expression of PBK1 expression in mammalian cells, tissues, or living body.

[0033] In another aspect, the invention comprehends the usage of transgenic mice with targeted deletion or overexpression of the PBK-1 gene to test efficacy and specificity of PBK-1 modulator compounds.

[0034] In a related aspect, the invention provides a method for in vivo screening for an agent that treats diabetes, said method comprising: a) subjecting a mammal comprising a PBK1 knockout genome to a diet that promotes diabetes; b) treating said mammal with a test agent; c) determining blood glucose level of said mammal; and d) determining whether said mammal is glucose tolerant. In one embodiment of the present invention, the animal is heterozygous for the PBK1 knockout. In another, the animal is homozygous for the PBK1 knockout.

DETAILED DESCRIPTION OF THE INVENTION

[0035] PBK1 (pancreas brain kinase), is shown herein to play a key role in regulating glucose-sensing. Overexpression of PBK1 in MIN6 cells greatly improves their glucose-sensing by more than three fold, much greater than that by GLP-1. Moreover, data detailed herein show that PBK1 also enhances insulin secretion stimulated by GLP-1 and other insulin secretagogues by improving the stimulus-secretion coupling function of β -cells. It is further demonstrated that PBK1 is a "master" regulator of the networks that regulate glucose-sensing, since PBK1 is associated with both synaptic-like microvesicles and insulin secretion granules. PBK1 is predominantly expressed in brain and pancreas, thus eliminating or reducing potential problems of functionally related side effects of an oral antidiabetic compound. Various embodiments described herein refer to type 1 diabetes and/or type 2 diabetes. For the purposes of the invention described herein these references to the types of diabetes are made consistently with the 1997 recommendations of the American Diabetes Association expert committee for universal adoption of simplified terminology, with which recommendations the National Institute of Diabetic and Digestive and Kidney Diseases (NIDDK) agreed. Accordingly, for the purposes of the invention described herein, type 1 diabetes encompasses art-recognized references to type I diabetes, juvenile diabetes, insulin-dependent diabetes mellitus, and/or IDDM; and type 2 diabetes encompasses art-recognized references to type II diabetes, adult-onset diabetes, noninsulin-dependent diabetes mellitus, and/or NIDDM.

[0036] In accordance with the present invention, various techniques and terms, including, but not limited to, conventional molecular biology, microbiology, immunology and

recombinant DNA techniques and terms may be used which are known by those of skill in the art. Such techniques and terms are described and/or defined in detail in standard references such as Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; Ausubel, F. et al., *Current Protocols in Molecular Biology*, John Wiley & Sons, 1994; Wild, D., *The Immunoassay Handbook*, 3rd Ed., Elsevier Science, 2005; Gosling, J. P., *Immunoassays: A Practical Approach*, Practical Approach Series, Oxford University Press, 2005; and Harlow, E. and Lane, D., *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 1988; and other references described herein.

[0037] PBK1 protein provided in compositions and methods described herein may be isolated from natural sources, such as brain or pancreas of an organism. Alternatively, PBK1 protein may be generated recombinantly, such as by expression using an expression construct, in vitro or in vivo. Nucleic acid sequences encoding PBK1 have been isolated as exemplified by nucleic acid sequences described herein along with amino acid sequences of PBK1. Methods and compositions are not limited to PBK1 having the amino acid sequence described herein in detail. Homologs, including orthologs, of PBK1 may be used. In addition, as will be appreciated by one of skill in the art, due to the degeneracy of the genetic code, more than one nucleic acid will encode an identical protein. Thus, nucleic acids encoding PBK1 or a homolog thereof are not limited to those nucleic acids described herein in detail.

[0038] "PBK1 protein" means a protein having at least 73%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the protein having a polypeptide sequence set forth in SEQ ID NO: 1, or a protein encoded by a nucleic acid sequence that hybridizes under high stringency hybridization conditions to the nucleic acid set forth in SEQ ID NO: 1 or a complement thereof so long as the protein effects the function described in the particular inventive method comprising use of the protein. For example, in a method of screening of the invention, a protein encoded by a nucleic acid sequence that hybridizes under high stringency hybridization conditions to the nucleic acid set forth in SEQ ID NO: 1 or a complement thereof is operable in the inventive method so long as the protein effects the described binding, kinase activity, or glucose-stimulated insulin secretion.

[0039] High stringency hybridization conditions are known to the ordinarily skilled artisan. For instance, high stringency conditions can be achieved by incubating the blot overnight (e.g., at least 12 hours) with a long polynucleotide probe in a hybridization solution containing 7% SDS, 0.5 M NaPO₄, pH 7, 1 mM EDTA at 65° C., followed by one or more washes with a 0.1% SDS, 1×SSC solution at 65° C. Whereas high stringency washes can allow for less than 5% mismatch, reduced or low stringency conditions can permit up to 20% nucleotide mismatch. A fragment of PBK1 protein is any fragment of a PBK1 protein that is operable in the described method utilizing the fragment, as understood by the ordinarily skilled artisan. A fragment of PBK1 protein is operative in any of the inventive methods described herein utilizing a PBK1 protein. For example, in a method of the invention comprising reacting a patient sample with a PBK1 protein or a fragment thereof under conditions that promote antibody-antigen binding, a fragment of the PBK1 will be such understood to be operative, so long as the fragment effects the described antibody-antigen binding. Furthermore, it is under-

stood by the ordinarily skilled artisan that such binding refers to specific binding as determinable by use of appropriate controls to distinguish it from nonspecific binding. Similarly, it is understood by the ordinarily skilled artisan that binding of a test agent or modulator to PBK1 protein refers to specific binding as determinable by use of appropriate controls to distinguish it from nonspecific binding.

[0040] "PBK1 DNA" means an isolated DNA molecule having a sequence that has at least 73%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the DNA sequence set forth in SEQ ID NO: 1, or an isolated DNA molecule having a sequence that hybridizes under high stringency hybridization conditions to the nucleic acid set forth in SEQ ID NO: 1 or a complement thereof, so long as the DNA effects the function described in the particular inventive method comprising use of the DNA. PBK1 DNA includes an isolated DNA molecule that has a sequence set forth in SEQ ID NO: 1, SEQ ID NO: 5, or SEQ ID NO: 18. A fragment of PBK1 DNA is any fragment of a PBK1 protein that is operable in the described method utilizing the fragment, as understood by the ordinarily skilled artisan. A fragment of PBK1 DNA is operative in any of the inventive methods described herein utilizing a PBK1 DNA.

[0041] A "test agent" or "modulator" as described in any of the inventive methods provided herein comprehends a compound; small molecule; biochemical; cytokine; biological including protein, peptide, antibody, or fragments thereof.

[0042] Conditions that promote binding, kinase activity, or glucose-stimulated insulin secretion as described in any of the inventive methods provided herein are well known in the art; including such conditions described in the references provided herein, and otherwise described or illustrated herein.

[0043] Methods of detecting type 1 diabetes are provided according to the present invention which include detecting an autoantibody in a patient sample by reacting the patient sample with a PBK1 protein. Detection of an autoantibody in the sample is indicative of type 1 diabetes in the patient. In particular embodiments, methods of the present invention for detecting type 1 diabetes are advantageously used to screen patients suspected of developing type 1 diabetes or likely to be susceptible to developing type 1 diabetes. For example, an inventive assay is used in a subject having a medical history or genetic background which predisposes the subject to development of type 1 diabetes.

[0044] Any of various techniques may be used to detect an autoantibody to PBK1 in a sample obtained from a subject. Standard immunomethods including, but not limited to, ELISA, radioimmunoassay, immunoblotting, immunoprecipitation assay, or immunodiffusion assay, may be used to detect an autoantibody to PBK1 in a sample. Immunomethods are described in detail in standard references such as Wild, D., *The Immunoassay Handbook*, 3rd Ed., Elsevier Science, 2005; Gosling, J. P., *Immunoassays: A Practical Approach*, Practical Approach Series, Oxford University Press, 2005; and Harlow, E. and Lane, D., *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 1988.

[0045] PBK1 protein or its peptide analogues may be immobilized on a solid support for incubation with the patient sample in particular embodiments.

[0046] PBK1 protein used in methods of the present invention for detection of type 1 diabetes is full-length PBK1 in particular embodiments. In further embodiments, an anti-

genic fragment of PBK1 is used. An antigenic fragment of PBK1 is a portion of a PBK1 protein which stimulates an immune response in a subject.

[0047] A patient sample is typically a blood, serum, plasma, and/or biopsy tissue sample. A particular biopsy tissue used in a method of the present invention is pancreas biopsy tissue. In addition to detection of type 1 diabetes, methods and compositions for use in treatment of diabetes are provided according to embodiments of the present invention.

[0048] In a particular embodiment, a mammalian pancreas-derived cell including a recombinant nucleic acid encoding PBK1 is provided. A mammalian pancreas-derived cell including a recombinant nucleic acid encoding PBK1 may be a primary pancreas cell, such as a pancreatic beta cell or a cell of a mammalian pancreas-derived cell line. In particular embodiments a cell of a mammalian pancreas-derived cell line is a Min6 cell. Further embodiments include any human pancreatic beta cell line including a recombinant nucleic acid encoding PBK1.

[0049] A method of treating type 1 diabetes in a subject is provided which includes delivering a mammalian pancreas-derived cell including a recombinant nucleic acid encoding PBK1 to a subject. In preferred embodiments, the cell is a glucose-sensing cell competent to secrete insulin. In particular embodiments, the mammalian pancreas-derived cell including a recombinant nucleic acid encoding PBK1 is delivered to the pancreas. In further embodiments, the microencapsulated mammalian pancreas-derived cell including a recombinant nucleic acid encoding PBK1 is delivered to liver or the kidney capsule of the subject.

[0050] An in vivo animal model for transplantation of exogenous cells expressing a transgene to the pancreas is exemplified by a model of type 1 diabetes generated by treatment of an animal with streptozotocin (STZ). Streptozotocin is well-known as a naturally occurring chemical that is particularly toxic to the insulin-producing beta cells of the pancreas. The STZ-diabetic animals will be transplanted with pancreatic beta cell line stably overexpressing PBK1 gene to test efficacy of the transplantation in the treatment of type 1 diabetes. Animals which may be used in a streptozotocin model of type 1 diabetes include, but are not limited to, rodents, rabbits and dogs.

[0051] In further embodiments, a nucleic acid encoding PBK1 is delivered to a subject to stimulate pancreatic beta cell differentiation and/or regeneration. Pancreatic β -cell differentiation/regeneration is measured by cell number counting and by immunofluorescence analysis of BrdU incorporation in pancreatic β -cell lines overexpressing the PBK-1 kinase.

[0052] Methods of identifying a PBK1 modulator are provided according to embodiments of the present invention which include contacting PBK1 with a putative modulator compound and assaying for a change in PBK1 activity. For example, a detected increase in PBK1 activity is indicative that the putative activator compound is an PBK1 activator. A detected decrease in PBK1 activity is indicative that the putative inhibitor compound is a PBK1 inhibitor. It is understood by the ordinarily skilled artisan that the detected increase or decrease in any of the inventive methods described herein comprehends reference to appropriate controls for the purposes of the particular method.

[0053] An assay used in methods of identifying a PBK1 modulator or in methods of screening described herein may have any of various formats, including, but not limited to,

cell-based and array assays. An array assay refers to an ordered array of one or more materials, such as an arrangement of addressable regions including putative activators, for example.

[0054] In particular embodiments, the inventive method includes detection of a change in secretagogue-stimulated insulin secretion, such as glucose-stimulated, GLP-1-stimulated and/or KCl-stimulated insulin secretion from a cell expressing PBK1. A cell expressing PBK1 is a mammalian pancreas-derived cell in particular embodiments of an inventive method. For example, a cell expressing PBK1 for use in an assay for detecting modulated PBK1 activity following contact with a putative modulator is a MIN6 cell containing a recombinant nucleic acid encoding PBK1.

[0055] Assays for modulator activity or for the screening described herein are optionally performed using a transgenic non-human animal, such as a transgenic mouse, having targeted deletion or overexpression of the PBK-1 gene, for example to test efficacy and specificity of PBK-1 modulator compounds. Methods for targeted deletion or overexpression of a gene in a cell and/or in an animal, such as a transgenic mouse, are known in the art as exemplified by description in references including, but not limited to, U.S. Pat. Nos. 5,994, 618 and 6,891,082, Nagy, A. et al., *Manipulating the Mouse Embryo: A Laboratory Manual*, 3rd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 2002 and Pinkert, C. A., *Transgenic Animal Technology*, A Laboratory Handbook, 2nd ed., Academic Press, 2002. See also Kishi M. et al. (2005) *Science* 37: 929-931.

[0056] A pharmaceutical composition for treatment of type 2 diabetes in a subject is provided which includes a modulator of PBK1. A PBK1 modulator is an activator or inhibitor of PBK-1 activity in particular embodiments.

[0057] In particular embodiments, a PBK1 modulator or agent described herein is formulated for oral delivery to a subject, in particular a subject having need of treatment for type 2 diabetes. In further embodiments, the pharmaceutical composition is formulated for parenteral, nasal, topical, ocular, buccal, pulmonary, or rectal delivery to the subject.

[0058] Formulation of pharmaceutical compositions for particular routes of administration is known in the art and is described in detail in references such as Allen, L. V. et al., *Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems*, 8th ed., Lippincott, Williams & Wilkins, 2005; and Remington: *The Science and Practice of Pharmacy*, 21st ed., Lippincott, Williams & Wilkins, 2006.

[0059] The terms "subject" and "patient" are used interchangeably herein and refer to individual animals, particularly mammals, including, but not limited to, humans.

[0060] The invention comprehends PBK1 as a drug target to screen compounds to be used for the treatment of type 2 diabetes. In particular embodiments, activators of AMPK (5'-AMP-activated protein kinase), related compounds and derivatives are PBK1 activators for the treatment of type 2 diabetes which improve glucose-sensing of the pancreatic beta-cells.

[0061] In further embodiments, inhibitors of PBK-1 are identified. PBK-1 inhibitors are useful, for instance, to prevent/treat hyperglycemia-induced apoptosis of pancreatic beta cells, or used as reference compounds in the methods described herein.

[0062] Embodiments of inventive compositions and methods are illustrated in the following examples. These examples

are provided for illustrative purposes and are not considered limitations on the scope of inventive compositions and methods.

EXAMPLES

Example 1

Cloning and Expression

Molecular Cloning of PBK1

[0063] The coding region of the human PBK1 cDNA (SEQ ID NO: 18; NCBI Acc. AF533876) is amplified by PCR from human fetal brain marathion-ready cDNA (BD Bioscience) using primers by 5'-CGATGACATCGACGGGGAAGGAC-3' (SEQ ID NO: 7) and 5'-GATGGCCTCGTGGAGGTGACATG-3' (SEQ ID NO: 8) and subcloned into Srf-1 site of pCR-Script-Amp SK(+) vector. A flag-tagged version of PBK1 is generated by PCR amplification by using primer pairs 5'-GCCACCATGGATTACAAGGATGACGACGATAAGACATCGACGGGGAAGGACGGCG GC-3' (SEQ ID NO: 9), and 5'-GATGGCCTCGTGGAGGTGACATG-3' (SEQ ID NO: 10). The resulting PCR product is cloned into Srf-1 sites of pCR-Script-Amp SK(+) vector, sequenced, and subcloned to the HindIII-NotI sites of pcDNA3.1.

Retrovirus Expression Vector

[0064] The insert is excised with BamHI-XhoI from pcDNA3.1-PBK1 and ligated into the BamHI and SalI sites of pBabe-puro to generate pBabe-PBK1 for retroviral expression in MIN6 cells.

Mutants

[0065] Site-directed mutagenesis is performed by using Quickchange multi-site kit (Stratagene). Amino acid residue Arg-48(K48M) or Thr-260(T260A) of PBK1 was replaced by Met and Ala, respectively. The primers for these two mutants are 5'-CCAGAAGGTGGCCATCATGATCGTCAACCGTGAG-3' (SEQ ID NO: 11) (K48M) and 5'-CGCCGCACGCCGCTCGCGCTAGAGCACATTCAG-3' (SEQ ID NO: 12) (T260A). The mutants are confirmed by sequencing analysis.

Cell Culture and Retroviral Infection

[0066] Pancreatic beta-cell line, Min6 cells, described in Miyazaki et al., *Endocrinology*, 1990 July; 127(1):126-32, are cultured in DMEM with 15% FBS, 25 mM glucose, 100 micromolar beta-mercaptoethanol, 100 units/ml penicillin/streptomycin. For retroviral infection, pBabe-puro constructs are used to transfect 293T-derived phoenix cells by the calcium phosphate method. Two days after transfection, supernatants containing viral particles are harvested and used to infect MIN6 cells. The cells are then selected by 1 microgram/ml puromycin.

Example 2

Human Tissue Distribution of PBK1 mRNA

[0067] Tissue distribution of PBK1 (pancreas brain kinase-1), also known as BRSK2, SAD1, SAD1, STK29, PEN11B, C11orf17 (18, 19) is examined. Northern blot analysis shows that PBK1 is almost exclusively expressed in human pancreas and brain, and most abundantly in human pancreas (FIG. 1);

implicating an important role for PBK1 in regulating pancreas function. Similar results were obtained when heart tissue was included in Northern blots. Northern blot analysis was carried out using multi-tissue blot from Clontech and radio-labeled human PBK1 as a probe.

Example 3

PBK1 Protein is Predominantly Expressed in Endocrine Islets

[0068] PBK1 protein expression were analyzed by western blot analysis using mouse monoclonal antibody to PBK1 and protein lysate from Min6 cells, pancreatic islets and exocrine pancreas isolated from C57B16 (B16), non-diabetic control db mouse (Db-C), hyperglycemic db mouse (Db-HG), or db mouse under normoglycemia (Db-LG), respectively. The same blot was also used to analyze the expression level of β -actin as an internal control for sample loading. The results showed that PBK1 is predominantly expressed in endocrine islet, but not detectable in exocrine pancreas. The results also showed that PBK1 protein expression was significantly up-regulated in islets of diabetic db mice. See FIG. 2.

Example 4

PBK1 Overexpression Improved Glucose-Sensing by Min-6 Cells

[0069] Min-6 is a stable cell line derived from mouse pancreatic beta cells (25). In comparison with other pancreatic beta-cell lines, MIN6 cells maintain the integrity of glucose-sensing ability. To achieve high transfection rates for the expression of PBK1 in MIN6 cells, a recombinant retroviral expression system was created for PBK1 as described above, and a flag tagged expression vector for PBK1 is generated to facilitate analysis of its expression in MIN6 cells, a mouse islet beta-cell line. As shown in FIG. 3, overexpression of PBK1 in MIN6 cells significantly enhances glucose and KCl stimulated insulin secretion. The effect of PBK1 on insulin secretion is fully dependent on its kinase activity.

[0070] The Min-6 cells were cultured in DMEM medium containing 4.5 g/l glucose and L-glutamine, and were infected with recombinant retroviruses overexpressing the human PBK1, a dominant negative mutant of PBK1 (DN), or a PKA phosphorylation defective mutant of PBK1 (T260A). The dominant negative mutant was generated by replacing lysine at aa 48 with methionine. The PKA defective mutant was generated by replacing threonine at aa 260 with an alanine. The infected Min-6 cells were selected for puromycin resistance as a stable pool. For measurement of glucose sensing by Min-6 cells, the stable pool of the infected Min-6 cells were preincubated for 1 hour at 37° C. in Krebs Ringer buffer containing 0 mM glucose, followed by 2 hour incubation with the indicated concentration of 2.8 mM, 16.7 mM, and 28 mM of glucose or 50 mM KCl. The supernatants were then collected and analyzed for insulin levels by radioimmuno assays using a kit from Linco Research, Inc. With respect to DN, mutation of the key amino acids for the kinase activation of PBK completely abolished its effect on insulin secretion. With respect to T260A, the mutant PBK1 partially lost its ability to improve insulin secretion by glucose and KCl (FIG.

3). The results showed that the wild type PBK1, but not the mutants, potentiated glucose- and KCl-stimulated insulin secretion.

Example 5

PBK1 Deficiency Impaired Glucose-Stimulated Insulin Secretion from Min-6 Cells

[0071] Endogenous mouse PBK1 (also known as SAD-A; BRSK2) and PBK2 (also known as SAD-B; BRSK1) mRNA expression was inhibited by transient transfection of Min-6 cells with 200 nM of siRNAs targeting the coding region of the mouse PBK1 (194-214: 5'-AGCGAGAGATTGC-CATCTTGA-3') (SEQ ID NO: 16) and PBK2 (468-488: 5'-GCCAGAGAACCTGCTGTTGGA-3') (SEQ ID NO: 17) coding regions or a scrambled-sequence siRNA as a negative control (Dharmacon) using Lipofectamine 2000 (Invitrogen). Efficiency of PBK1 and PBK2 knockdown were assessed by RT-PCR. The results showed more than 70% reduction of the endogenous PBK1 and PBK2 mRNA expression (A). Sixty hours after the transfection, insulin secretion was analyzed from the Min-6 cells as described in FIG. 4. The results showed that deficiency of PBK1, but not PBK2, resulted in impaired glucose sensing by Min-6 cells (B).

Example 6

PBK1 Deficiency in Mice Caused Diabetes

[0072] Oral glucose tolerance test were carried out in awakening PBK1 heterozygous knockout mice and the wild type controls to analyze the onset of diabetes. The heterozygous PBK1 knockout (n=4) and the wild type control mice (n=4) at three months of age on regular chow were fasted overnight and then analyzed for blood glucose levels using blood samples collected by tail bleeding (0 min). The mice were then given 50% glucose solution by oral gavage at 2.5 g glucose/kg body weight. Blood samples were collected from tail-bleeding at 30, 60, and 120 minutes, respectively, after the glucose overload and analyzed for glucose levels by glucose meter. The results (FIG. 5) showed that the heterozygous PBK1 knockout mice have higher fasting blood glucose level (panel A). One of the heterozygous mice developed diabetes as judged by the fasting blood glucose level and glucose tolerance test (panel B).

Example 7

Subcellular Fractionation of PBK1

[0073] PBK1 is associated with both synaptic-like microvesicles and insulin secretion granules. Subcellular localization of the recombinant PBK1 in MIN-6 cells was analyzed by sucrose gradient and Western blot analysis using markers for synaptic-like microvesicles and insulin secretion granules. As shown by FIG. 6, the recombinant PBK1 is co-localized with both Rim2 and VAMP2 in subcellular fractions segregated by sucrose gradient. Rim2 is a putative effector protein for Rab3s, synaptic GTP-binding proteins. RIM2 is localized close to the active zone at the synapse and regulates neurotransmitter releases (20). In insulin-secreting β -cells, Rim2 interacts with cAMP-binding protein cAMP-GEFII (or Epac 2), and mediates cAMP-dependent, PKA-independent insulin secretion (21). VAMP2 is associated with insulin secretory granules and regulates insulin exocytosis from pancreatic β -cells (22). The data support a dynamic role

of PBK1 in regulating insulin secretion by interacting with proteins of different networks involved in insulin secretion.

[0074] Sucrose gradient fractionation is performed by the method of Mizuta et al (17). Briefly, a stable MIN6 cell clone overexpressing PBK1 is harvested by homogenization buffer containing 200 mM sucrose, 50 mM NaCl, 2 mM EGTA, 10 mM HEPES at pH7.2, and 1 mM phenylmethylsulfonyl fluoride and homogenized. The homogenate is centrifuged at 1770 g for 6 min at 4° C. The resulting postnuclear supernatant is applied to the top of sucrose gradients (0.4, 0.6, 0.8, 1.0, 1.4, 1.8 M) in 10 mM HEPES, pH 7.2, and 2 mM EGTA, and centrifuged at 55,000 g for 2 hours at 4° C. The fractions are collected from the top to bottom, precipitated with 15% trichloroacetic acid, and subjected to immunoblot analysis using anti-Flag antibody (Sigma), anti-Rim2 antibody (Synaptic Systems), and anti-VAMP2 antibody (Calbiochem).

Example 8

Polymorphism Analysis for Early Diagnosis of Type 1 Diabetes and Type 2 Diabetes

[0075] PBK1 is localized on chromosome 11p15.5, an IDDM2 diabetic locus. Sequence analysis of the 3'-untranslated region revealed a polymorphism, described in Miura et al. (18), which can be used to predict the onset of type 2 diabetes. The polymorphism will be investigated by analyzing the patterns of DNA fragments from HhaI/BstUI digestion of genomic DNAs of the 3' untranslated region of PBK1 gene from diabetic and non-diabetic subjects. The genomic DNAs from diabetic and non-diabetic subjects will be amplified by PCR reactions (35 cycles of 94° C. for 30 seconds, 59° C. for 30 seconds, and 72° C. for 90 seconds) using a primer pair: 5'-GTCACCTGACCCCTCAGCAA-3' (SEQ ID NO: 13) and 5'-CACCAGCTCTGTCCTCAGAG-3' (SEQ ID NO: 14). The PCR product will be purified by Qiaquick PCR purification kit (Qiagen), digested with HhaI/BstUI, and separated on a 6% polyacrylamide gel.

Example 9

Early Diagnosis of Type 1 Diabetes

[0076] Type 1 diabetes is caused by autoimmune destruction of pancreatic beta cells, which generally occurs over a period of several years leading to the eventual onset of overt diabetes mellitus. During this extended pre-clinical phase, the characteristic circulation of autoantibodies against a variety of islet cell antigens including glutamic acid decarboxylase (GAD65), IA-2 (a tyrosine phosphatase-like protein), and insulin provides early markers of autoimmune disease activity as well as early diagnosis of type 1 diabetes. The present invention comprehends PBK1 as an autoantigen in type 1 diabetes, and that the autoantigen can be used as a marker for early diagnosis of type 1 diabetes by using enzyme-linked immunosorbent assay (ELISA), radioimmuno assays (RIA), and the like. In the ELISA assay, purified PBK1 protein will be used to detect the presence of autoantibodies to PBK1 from serum of type 1 diabetic patients. Methods for detecting presence or absence of autoantigens are known to the ordinarily skilled artisan. For example, such methods have been applied to detect presence or absence of GAD65 and other autoantigens (23).

Example 10

Application to Type 2 Diabetes

[0077] PBK1 can be used as a drug target to screen activator compounds for the treatment of diabetes, obesity, diabetic

retinopathy, and other metabolic diseases. The screening process illustratively comprehends binding assay, kinase assay, and functional assay. PBK1 activators can be identified by measuring the binding potency of the compounds to the kinase ATP binding site through competition with a conjugated binding probe as described in reference 24. PBK1 activators are expected to stimulate kinase activity in a kinase assay. In the PBK1 kinase assay, purified PBK1 from *E. coli* or sf-9 insect cells are incubated in a kinase buffer (Cell Signaling Technology, USA) in the presence of 0.5 mM LNR peptide (KKLNRTLSEFAEPG) (SEQ ID NO: 15) in the presence of 10 μ M ATP, and 1 μ l [γ - 32 P]-ATP (5 μ Ci). After incubation at 30° C. for 30 min, 15 μ l acetic acid is added to stop the reaction. The kinase activity is quantified by radioactivity incorporated into the LNR peptide using phosphocellulose P-81 filter squares. For high throughput kinase assay for PBK1 activators, purified PBK1 protein is incubated with sepharose beads coupled with LNR peptide in the kinase buffer in the presence of 0.2 mM of [γ - 32 P]-ATP for 30 min, and then washed three times before scintillation counting of radioactivity. In the functional assay, PBK1 activators are expected to potentiate glucose stimulated insulin secretion from isolated islet beta cells or cultured pancreatic beta cell lines, such as Min-6 cells. In this assay, addition of a PBK1 activator potentiates glucose stimulated insulin secretion in a glucose-dependent manner, but is ineffective in the absence of glucose, as demonstrated by FIG. 3.

Example 11

Sequence Data

[0078] SEQ ID NO.'s: 1 and 2 are with reference to: Accession NO. NM_003957; 3506 bp; *Homo sapiens* BR serine/threonine kinase 2 (BRSK2) setting forth:

```

/translation =
"MTSTGKDGGAGHAQYVGPYRLEKTLGKGQTGLVKLGVCVTCQK

VAIKIVNREKLSSEVLMKVEREIAILKLI EHPHVLKLHDVYENKKYLYLVLEHVS GGE
LFDYLVKKGR LTPKEARKFFRQIIISALDFCHSHSICHRLKPENLLLEKNNIRIADP
GMASLQVGD SLLSETSCGSPHYACPEVIRGEKYDGRKADVWSCGVILFALLV GALPDD
DNLRLQLEKVKRGV FHPMPHFIPDP CQSLRGMI EVDAARRLTLEHI QKHIWYIGGKNE
PEPEQPIPRKVQIRSLPSLEDIDPDVLD SMHSLGCFDRNKLQDLLSEENQEKMIY
FLLDDRKERYPSQ EDEDLPPRNEIDPPRKRVDS PMLNRHGKRRPERKSMEVLSVTDGG
SPVPARRAIE MAQHQRSRISGASSGLSTSLSSPRVTPHPSRGSPLPTPKGTVPVH
TPKESPA GTPNPTPPSSPSVGGVPWRARLNS IKNSFLGSPRFHRRKLQVPTPEEMSNL
TPESSPELAKKSWFGNFISLEKEEQIFVVIKDKPLSSIKADIVHAFLSIPLSHSHVIS
QTSFRAEYKATGGPAVFQKPKVFQVDITYTEGGEAQKENGIIYSVTF TLLSGPSRRFKR
VVETIQAQLLSTHDP PAAQLHSDTTNCMEMMTGR LSKCGIIPKS"

ORIGIN
1  gctgttcggc tcagctgcac ggctcggctc ggctcggctc ggctcggctg cgcggccgct
61  gacgggctg cgctgggggc gggggcgcg gggcggggc ctcggcgcg cgcggcgcg
121 cgcgggcgga agccaggctc cccgccccg cctgtcctc cgacgagcg gagcgctcg
181 cgcgggccag gcctcggact gcgcgctcg agtggaacg gggggcgcg gcgcggcg
241 acgcggggcg cgcaagcag cggggcccg gggggcgccc cggccgggtc ggcgcggag
301 gcactcggcg gacgcggcg gacgtgggc gggccctcc tggcgcgcg cccggcgcc
361 cctggcggc gccggggccc agagcgatga catcgacgg gaaggacgg ggcgcgagC
421 acgcgcagta tggtgggcc taccggctg agaagacgt gggcaaggg cagacaggtc
481 tggtgaagct ggggggttc tcgctcacct gccagaagg gggcatcaag atcgtaacc
541 gtgagaagct cagcgagtc gtgctgatga aggtggagc ggagatcgc atcctgaag
601 tcattgagca ccccccagtc ctaaagctg acgacgttta tgaacaaaa aaatattgt
661 acctggtgct agaacacgtg tcaggtggt agctcttcga ctacctgtg aagaagggg
721 ggctgacgc taaggaggct cggaagttc tccggcagat catctctgc ctggacttct
781 gccacagcca ctccatatg cacagggatc tgaacctga aaacctctg ctggacgaga
841 agaacaacat ccgcatcgca gactttggc tggcgctcct gcaggttggc gacagcctgt

```

-continued

901 tggagaccag ctgtgggtcc cccactacg cctgccccga ggtgatccgg ggggagaagt
961 atgacggccg gaaggcgac gtgtggagct gcggcgcat cctgttcgcc ttgtgtgtgg
1021 gggctctgcc cttcgacgat gacaacttgc gacagctgct ggagaagggt aagcggggcg
1081 tgttcacat gccgcacttt atccccccg actgccagag tctgctacgg ggcagatcg
1141 aggtggacgc cgcacgcgc ctcacgctag agcacattca gaaacacata tggatatag
1201 ggggcaagaa tgagcccgaa ccagagcagc ccatttcctg caagggtcag atccgctcgc
1261 tgcccagcct ggaggacatc gaccccgacg tgctggacag catgcactca ctgggctgct
1321 tccgagacgg caacaagctg ctgcaggacc tgctgtccga ggaggagaac caggagaaga
1381 tgatttactt cctcctcctg gaccggaaaag aaaggtaacc gagccaggag gatgaggacc
1441 tgccccccg gaacagata gaccctccc ggaagcgtgt ggactcccc atgctgaacc
1501 ggcacggcaa gcggcgccca gaacgcaaat ccattggagg gctcagcgtg acggacggcg
1561 gctccccgtt gcctgcgcgg cgggccattg agatggccca gcacggccc aggtctcgtt
1621 ccacagcgg tgctctctca ggcttttcca ccagccact cagcagcccc cgggtgaccc
1681 ctcacccctc accaaggggc agtccctcc ccaccccaa ggggacacct gtccacacgc
1741 caaaggagag cccggctggc acgcccaccc ccacgcccc gtccagcccc agcgtcggag
1801 ggggtccctg gagggcgcg ctaactcca tcaagaacag ctttctggg tcaccccgct
1861 tccaccgcgg gaaactgcaa gtccgacgc cggaggagat gtccaacctg acaccagagt
1921 cgtccccaga gctggcgaag aagtctcgt ttgggaactt catcagcctg gagaaggagg
1981 agcagatctt cgtggctatc aaagacaaac ctctgagctc catcaaggct gacatcgtgc
2041 acgcttctc gtgcattccc agtctcagcc acagcgtcat cccccaaag agcttcggg
2101 ccgagtaaaa ggcacgggg gggccagccg tgttcagaa gccggtcaag ttccaggttg
2161 atatcaccta caggagggtt ggggagggc agaaggagaa cggcatctac tccgtcacct
2221 tcacctcgt ctcaggcccc agcgtcgtc tcaaggagg ggtggagacc atccaggccc
2281 agctgtgag cacacacgac ccgctcgcg ccagcactt gtcagacacc actaactgta
2341 tggaaatgat gacggggcg ctttccaaat gtggaattat cccgaaaagt taacatgtca
2401 cctccacgag gccatctct gtgaccgaag gcagctgctg cggacccgcc ctccctcgc
2461 tctgtctgtt gctgccgggc agtgaggccc agcccagcgc cccgtccacc ccgcccagc
2521 tcctcgcctc agctccgcac ggcccgtggg aggaaggcca ggctcggggg agcctcctcc
2581 agccccggcg acccggaact ccggtcacct gacccctcag caagaacagc ctgctcgtg
2641 gccttctggg gccaggaccc ctggtgggca acgtagccac aggaacaggc cccgtccacc
2701 gcctccacgc cgcacctgga ggctcctcgc caggcccggt ccccgccctc ctggctcgc
2761 cgctccgtg tagtcttggc ctctcagge tgctcccgct cctctcgtct caccgcgc
2821 tcccttgct catctggggc ggctgtgggc tctggcgctc ctctctggt gaggtggaaa
2881 cagagacacc ctgcggcacc agagccttcc cagcaggcca ggccgctggg ctgggatcag
2941 tgttatttat ttgcggtttt aatttatgga ttctccgcac ctctgttcag ggaaggcg
3001 cggccacatc ccctgcgcgc tcgtgtctc aggcagtggt ggggctgggg ccagggcgc
3061 ctctgaggag agagctgggt gggcgcggg gggctggcga gctactgtaa actttaaaga
3121 attcctgcaa gatattttta taaactttt tttcttggtg gtttttgaa aagggtgtg

-continued

3181 ggggtgggggc gccgctgggg cagggccagg tttgtgttt tagtccttg ctctgettc
 3241 tttctacaca cacatctaaa gacgggtgcg ctcgctctgt catgggttcc gtctctctgt
 3301 ggagaagcag ctccacctct gggggggctc ggggcagagg ggcggtgtct cgtagcgggc
 3361 ggcagcgcca gcgccccctc gtcaggctgg ggcaatcttg gttttgtgtc caaaggtaga
 3421 ggggtaggag gagggccctc agctggccct cccacacac aggacggcag gggcactgtg
 3481 aggcctttct tattaataatg aaaaaa

[0079] SEQ ID NO.'s: 3 and 4 are with reference to: Accession NO. NM_032430; 3109 bp; *Homo sapiens* BR serine/threonine kinase 1 (BRSK1) setting forth:

/translation =

"MSSGAKEGGGSPAYNLPHPHPPQHAQYVGPYRLEKTLGKGQ

TGLVKLGVHCITGQKVAIKIVNREKLSSEVLMKVEREIAILKLIHHPVHLKLDVYEN
 KKYLYLVLENVSGGELFDYLVKKGR LTPKEARKFFRQIVSALDFCHSYSICHRDLKPE
 NLLLDEKNIRIADFGMASLQVGDSLLETSCGSPHYACPEVIKGEKYDGRADMMWSCG
 VILFALLVGLPFDNLRQLLEKVKRGVFMHPHFIPDCQSLLRGMIEVEPEKRLSL
 EQIQKHPWYLGKHEPDPCLEPAPGRRVAMRSLPSNGELDPDVLESMA LGCFRDRER
 LHREL RSEENQEKMIYYLLDRKERYPSCEDQDLPPRNDVDPKRKVDSPMLSRHGK
 RRPERKSMEVLSITDAGGGSPVPTRRALEMAQHSQRSRSVSGASTGLSSPLSSPRS
 PVFSFSPGAGDEARGGGSPTSKTQTLPSRGPRGGGAGEQPPPSARSTPLPGPPGS
 PRSSGGTPLHSPLHTPRASPTGTPTGTPPPSPGGVGGAAWRSRLNSIRNSFLGSPRF
 NRRKMQVPTAEEMSSLTPESSPELAKRSWFGNFISLDKEEQIFLVLDKDKPLSSIKADI
 VHAFSLIPSLSHSVLSQTSFRAEYKASGGFSVFQKPVRFQVDISSSEGPEPSPRDGS
 GGGGIYSVFTLISGPSRRFKRVVETIQALLSTHDQPSVQALADEKNGAQTRPAGAP
 PRSLQPPGPRDPELSSSPRRGPPKDKLLATNGTLP"

ORIGIN

1 gggggccggc cagaaacggg ctggggaggg ggggccccgc agccccctg ggccatgctg
 61 actcccgggg cctgaccccc ccgggccagc cccccctccc ccagctccgc ggcccgccga
 121 ctgggggggg ccagcccagc cccctgggga ccccgagaga ggtggggggc agccgggggg
 181 gccgggacgg agcggctcgc ggccccacc ggagagacgg ggcgacggcc gcaggggggg
 241 cgcccggggg accggctcgg ccgggaccaa gggcaccatg tcgtccgggg ccaaggaggg
 301 aggtgggggc tctcccgctt accacctccc ccacccccac cccacccac cccagcacgc
 361 ccaatatgtg ggccccatc ggctggagaa gacgctgggc aaaggacaga cagggtggt
 421 taaactcggg gtccactgca tcacgggtca gaaggtcgc atcaagatcg tgaaccggga
 481 gaagctgtcg gactcgggtc tgatgaaggt ggagcgggag atcgccatcc tgaagctcat
 541 cgaacacca catgtcctca agctccacga cgtctacgag aacaagaaat attgtacct
 601 ggttctggag cactctcgg ggggtgagct attcgactac ctggtaaaga aggggagact
 661 gacgccccaa gagggccgaa agttcttcgg ccagattgtg tctgcgctgg acttctgcc
 721 cagctactcc atctgcaca gagacctaaa gcccgagaac ctgcttttg atgagaaaa
 781 caacatccgc attgcagact tcggcatggc gtcctgcag gtgggggaca gcctcctgga

-continued

841 gaccagctgc gggcccccc attatgcgtg tccagagggtg attaaggggg aaaaatatga
901 tggccgcccgg gcagacatgt ggagctgtgg agtcacccctc ttcgcccctgc tcgtggggggc
961 tctgcccttt gatgacgaca acctccgcca gctgctggag aagggtgaaac ggggcgtctt
1021 ccacatgccc cacttcattc ctccagattg ccagagccctc ctgaggggaa tgatcgaagt
1081 ggagcccga aaaaggctca gtctggagca aattcagaaa catccttggc acctaggcgg
1141 gaaacacgag ccagaccctg gcctggagcc agcccctggc cgcgggtag ccatgcggag
1201 cctgccatcc aacggagagc tggaccccg cgtcctagag agcatggcat cactgggctg
1261 cttcagggag cgcgagaggc tgcacgcga gctgcgcagt gaggaggaga accaagaaaa
1321 gatgatatat tatctgtttt tggatcggaa ggagcggat cccagctgtg aggaccagga
1381 cctgcctccc cggaatgatg ttgaccccc ccggaagcgt gtggattctc ccatgctgag
1441 ccgtcacggg aagcggcgac cagagcggaa gtccatggaa gtctgagca tcaccgatgc
1501 cgggggtggt ggctcccctg taccaccccg acgggccttg gagatggccc agcacagcca
1561 gagatcccgt agcgtcagt gaggctccac gggctctgtc tccagccctc taagcagccc
1621 aaggagtcgg gtcttttctt ttaccggga gccgggggct ggagatgagg ctgaggcgg
1681 gggctcccgt acttccaaaa cgcagacgct gccttctcgg gggcccaggg gtggggcgcc
1741 cggggagcag ccccgcccc ccagtgcctg ctccacaccc ctgcccggcc cccaggtcc
1801 cccgcgtcc tctggcgga ccccttgca ctgcctctg cacacgccc gggccagtcc
1861 caccgggacc ccggggacaa caccacccc cagcccggc ggtggcgctg ggggagccgc
1921 ctggaggagt cgtctcaact ccatccgcaa cagcttctg ggtcccctc gctttcaccc
1981 gcgcaagatg caggtcccta ccgctgagga gatgtccagc ttgacgccag agtccctccc
2041 ggagctggca aaacgctcct ggctcgggaa cttcatctcc ttggacaaaag aagaacaaat
2101 attcctcgtg ctaaaggaca aaactctcag cagcatcaaa gcagacatcg tccatgcctt
2161 tctgtcgatc cccagctga gtcacagtgt gctgtcacag accagcttca gggccgagta
2221 caaggccagt ggcgccccc cgtcttcca aaagccgctc cgttccagg tggacatcag
2281 ctctctgag ggtccagagc cctccccgcg acgggacggc agcggagggtg gtggcateta
2341 ctccgtcacc ttcactctca tctcgggtcc cagccgtcgg ttcaagcgag tgggtggagac
2401 catccagga cagctctga gcaactatga ccagccctcc gtgcaggccc tggcagacga
2461 gaagaacggg gccagacccc ggctgctgg tgcacacccc cgaagcctgc agccccacc
2521 cggccgcca gaccagagc tgagcagctc tccccgcga gggccccca aggacaagaa
2581 gtccttgccc accaacggga cccctctgcc ctgaccccac ggggcccggg agggagggga
2641 cccccctca cccccctcc gtgccccca actgtgaatc tgtaataaag gccaaggaa
2701 catgtcggga ggggggtgga caaaaaac ggcttgccc tgcagggatg gggctccaca
2761 gccgctgccc aactgggggt ggttctaggg gaacaggggg cgggggagct gtttctattt
2821 tattttattga ttaatttatt attttttta ttgatcaatc tctctcggg gtggggtggg
2881 ggagggacgg gagctggtt gggtggctta gcagatccgg acagggccct ctgtccctgt
2941 gtgctccca accccctct cccgggccc tctccctg gtctccccc cagaccttc
3001 tgtacggatt tgctctccg aaggaattct ggttctcgt gatcctgcct gcgtccgtgt
3061 ctctgatccc gccggcgga aaaaaaaaa aaaaaaaaa aaaaaaaaa

[0080] SEQ ID NO's. 5 and 6 are with reference to:

```

NEDO human cDNA sequencing project; 3576 b.p.; Ninomiya, K. et al.
/organism = "Homo sapiens"
/mol_type = "mRNA"
/db_xref = "taxon:9606"
/clone = "BRAMY3018357"
/tissue_type = "amygdala"
/clone_lib = "BRAMY3"
/note = "cloning vector: pME18SFL3"
CDS 254 . . . 2554
/note = "unnamed protein product"
/codon_start = 1
/protein_id = "BAD18671.1"
/db_xref = "GI:47077575"

/translation =
"MSPEGHPSRWARPRRPCICPSSLCSPREPRSGPAVGRGGAHHR

VPAGHTPGPQLLQPHLHLPQGQTWLCQPSPAGLVKLGVCVTCQKVAIKIVNREKLS
ESVLMkVEREIAILKLI EHPHVLKLDVYENKKYLYLVLEHVS GGELFDYLVKKGRLT
PKEARKFFRQIISALDFCHSHSICHRDLKPENLLLDEKNNIRIADFGMASLQVGD SLL
ETSCGSPHYACPEVIRGEKYDGRKADVWSCGVILFALLVGALPFD DNLRLQLEKVKR
GVFHMHPHFIPDCQSLLRGMI EVDAARRLTLEHIQKHIWYIGGKNEPEPEQPIPRKVQ
IRSLPSLEDIDPDVLDMSHSLGCFDRNXLLQDLLSEENQEKMIYFLLLD RKERYPS
QEDEDLPPRNEIDPPKRVDSPMLNRHGKRRPERKSMEVLSVTDGGSVP PARRAIEMA
QHQRSRISISGASSGLSTSP LSSPRVTPHPSPRGSPLPTPKGTPVHTPKESPAGTPNP
TPPSSPSVGGVPWRARLNSIKNSFLGSPRFHRRKLQVPTPEEMSNLTP ESSPELAKKS
WFGNFISLEKEEQIFVVIKDKPLSSIKADIVHAFLSIPSLSHSVISQTSFRAEYKATG
GPAVFQKPVKQVDITYTEGGEAQKENGIVSVTFTLLSGPSRRFRKRVETIQ AQLLST
HDP PAAQHLSDTTNCMEMMTGRLSKCDKNGQAAQAPSTPAKRSAHGPLGDSAAAGPG
PGGDAEYPTGKDTAKMGPP TARREQP"

ORIGIN
    1 agtctcaggc tggctagttc ctccttctcg gtcactgagc cagccttgct gaggggagag
   61 cgggttcttg acgtgctctg agcttccttc ctcacagcct tgctcctggg ccagatcagc
  121 aggaaagcag ccaatgcccc gccatggcct gcccggttgg ggtcctgaag ctggggccgg
  181 agcagggggc acagtctctg cccatctggc cctagtcttg ggaggagacc tggtagggca
  241 ccagcctcac cccatgagcc ctgagggcca cccagccga tgggcacgtc cccgccggcc
  301 ctgcatctgt ccttcctccc tctgctcccc aagagagccc aggtctggcc cagcgggtggg
  361 caggggaggg gccgcacatc acagagtgcc agctggccac actccgggcc cacagctgct
  421 ccagccgcac ctccaccttc ctcaaggcca gacctggtc tgctgcagc ccagcccagc
  481 aggtctggtg aagctggggg ttcactgctg cacctgccag aaggtggcca tcaagatcgt
  541 caaccgtgag aagctcagcg agtcggtgct gatgaagggt gagcgggaga tcgcgatact
  601 gaagctcatt gagcaccccc acgtcctaaa gctgcacgac gtttatgaaa acaaaaaata
  661 tttgtacctg gtgctagaac acgtgtcagg tggtagctc ttcgactacc tggatgaaga
  721 ggggaggctg acgcctaagg aggtctggaa gttcttcogg cagatcatct ctgcgctgga
  781 cttctgccac agccactcca tatgccacag ggatctgaaa cctgaaaacc tcctgctgga
  841 cgagaagaac aacatccgca tcgcagactt tggcatggcg tcctgcagc ttggcgacag
  901 cctgttgtag accagctgtg ggtcccccca ctacgcctgc cccaggtga tccgggggga

```

-continued

961 gaagtatgac ggccggaagg cggacgtgtg gagctgcggc gtcacacctgt tcgccttgct
1021 ggtgggggct ctgcccttcg acgatgacaa cttgcgacag ctgctggaga aggtgaagcg
1081 gggcggtgtt caccatgcgc actttatccc gcccgactgc cagagtctgc tacggggcat
1141 gatcgagggtg gacgcgcac gccgcctcac gctagagcac attcagaaac acatatggta
1201 tatagggggc aagaatgagc ccgaaccaga gcagcccatt cctcgcaagg tgcagatccg
1261 ctgcctgccc agcctggagg acatcgaccc cgacgtgctg gacagcatgc actcactggg
1321 ctgcttccga gaccgcaaca agctgctgca ggacctgctg tccgaggagg agaaccagga
1381 gaagatgatt tacttctccc tcctggaccg gaaagaaagg tacceagacc aggaggatga
1441 ggacctgccc ccccggaacg agatagaccc tcccgggaag cgtgtggact CCCGatgCt
1501 gaaccggcac ggcaagcgcc ggccagaacg caaatccatg gaggtgctca gcgtgacgga
1561 cggcggtccc ccggtgcctg cgcggcgggc cattgagatg gccagcacg gccagaggtc
1621 tcgggtccatc agcgggtgct cctcaggcct ttccaccagc cactcagca gccccgggt
1681 gacccctcac ccctaccaa ggggcagtcc cctcccacc cccaagggga cactgtcca
1741 cagcccaaag gagagcccg ctggcacgcc caacccacg ccccgtcca gcccagcgt
1801 cggagggtg ccctggagg cgcggtcaa ctccatcaag aacagcttcc tgggtcacc
1861 ccgcttccc gcgcggaac tgcaagtccc gacgcggag gagatgtcca acctgacacc
1921 agagtcgtcc ccagagctgg cgaagaagtc ctggtttggg aacttcata gcctggagaa
1981 ggaggagcag atcttcgtgg tcataaaga caaacctctg agctccatca aggtgacat
2041 cgtgcacgcc ttctgtoga ttcccagtc cagccacagc gtcactccc aaacgagctt
2101 ccgggcccag tacaaggcca cgggggggccc agcgtgttc cagaagccg tcaagttcca
2161 ggttgatc acctacacg aggggtggga ggccgagaag gagaacggca tctactccgt
2221 cacttccac ctgctctcag gccccagccg tcgcttcaag aggggtggtg agaccatcca
2281 ggcccagctg ctgagcacac acgacccgcc tgcggcccag cacttctcag acaccactaa
2341 ctgtatgga atgatgacg ggccgcttcc caaatgtgac gagaagaac ggccggcgcc
2401 ccaggccccc agcacgccc ccaagcggag tgcccacggc cactcgggtg actccgcggc
2461 cgctggccct ggccccggag gggacgccga gtacccaacg ggcaaggaca cggccaagat
2521 gggcccgccc accgcccgcc gcgagcagcc ttagacacac tagccccccc cccagcaca
2581 gactgacag cggctgcctc gcgcgccgc gcccgccctg ccccgagtgg acccgcgccc
2641 gcgcgcgcc tcgctccaga ctgttctcag agcctgggag gaaaggaaag gggcggtggg
2701 gcgcgctgt gggctgcgc acccgcgccc gctctcttt ctctctgtct ctgcctctgc
2761 ctgtctctga cagcatcgct tgtttccact ctgataccag gaattatccc gaaaagttaa
2821 catgtcacct ccacgaggcc atctctgtg accgaaggca gctgctgcg acccgccctc
2881 cctccgctc tgcgtgtgct gccgggcagt gagggccagc ccagcgcgc gtccacccc
2941 cggcagctcc tcgcctcagc tccgcacggc ccgtgggagg aaggccagc tcgggggagc
3001 ctctccagc ccggccgacc cggactccc gtcacctgac cctcagcaa gaacagcctg
3061 cctggtggcc ttctggggcc aggacccctg gtgggcaac tagccacag aacaggcccc
3121 gtccaccgcc tccagcgc acctggaggc ctctctcag gcccgctccc cgcctccctg
3181 gccgcgcgc ctccgtgtag tcttgccctc ctccgctgc ctccgctcc ctgctctcac

-continued

3241 ccgcgcctcc cttgcctcat ctggggcggc tgtgggtctt ggcgtctctc tctggctgag
 3301 gtggaacacag agacaccctg cggcaccaga gccttcccag caggccaggc cgctgggctg
 3361 ggatcagtgt tatttatttg ccgttttaatt ttatggattc tccgcacctc tgttcaggga
 3421 agggcgcgccg ccacatcccc tgccgtctgc gtgtctcagg cagtgggggg gctggggcca
 3481 gggcgccctc tgaggacaga gctggtgggg cgcggggggg ctggcgagct actgtaaact
 3541 ttaaagaatt cctgcaagat atttttataa actttt

[0081] SEQ ID NO.'s: 18 and 19 are with reference to:
 Accession NO. AF533876; 3117 bp; *Homo sapiens* BR
 serine/threonine kinase 1 (BRSK2) setting forth:

/translation =

"MTSTGKDGGQAQYVGPYRLEKTLGKGQTGLVKLGVHCVTCQK

VAIKIVNREKLSSEVLMKVEREIAILKLIHPPHVLKLDVYENKKYLYLVLEHVSNGE
 LFDYLVKKGRLLTPKEARKFFRQIISALDFCHSHSICHRLDKPENLLDEKNNIRIADF
 GMASLQVGDLSLETSCGSPHYACPEVIRGEKYDGRKADVWSCGVILFALLVGALPFDD
 DNLRQLLEKVKRGVFMHPHFIPDCQSLRGMSEVDAARRLTLEHIQKHIWIYIGKNE
 PEPEQPIPRKVQIRSLPSLEDIDPDVLDMSHSLGCFDRNKLQDLLSEENQEKMIY
 FLLLDRKERYPSQEDDLPRNEIDPPKRVDSPMLNRHGKRRPERKSMEVLSVTDGG
 SPVPARRAIEMAHQGRSRSISGASSGLSTSPSSPRVTPHPSPRGSPPLTPKGTTPVH
 TPKEPAGTNPNTPPSSPSVGGVPWRARLNSIKNSFLGSPRFHRKLQVPTPEEMSNL
 TPESPELAKSWFGNFISLEKEEQIFVVIKDKPLSSIADIVHAFSLPSLSHVIS
 QTSFRAEYKATGGPAVFQKPVKFQVDITYTEGGEAQKENGIIYSVTFTLLSCPSRRFKR
 VVETIQALLSTHDPAAQHLSDTTNCMEMMTGRLSKCGIIPKS

ORIGIN

1 tgttcggctc agctgcacgg ctccgctcgg ctccgctcgg ctccgctcgg cggccgctga
 61 cgggctgctg ctggggcgcc gggcgcgagg gcgcgggcct cggcgcgagg ggcggcgagg
 121 gcggcggaag ccagggtccc ccgcccggcc tgctctctcg acgaggcgga ggctgcgccg
 181 cgggcccagg ctcggactgc cgcgtcggag tggacgcggg gggcgcgagg gcggcgaggc
 241 gcggcgggcg cgaagcagcg gggcccgcg gggcgccccg gccgggtcgg cgcggacggc
 301 actcggcgga cgcggggcga cgtggggcgg cccctccctg cccgcgcgcc cggcgcccc
 361 tggccggcgg tgggccccag agcgatgaca tcgacgggga aggacggcgg cgcgcagcac
 421 gcgcagtatg ttgggcctta ccggctggag aagacgtgg gcaaggggca gacaggtctg
 481 gtgaagctgg gggttcactg cgtcacctgc cagaaggtgg ccatcaagat cgtcaaccgt
 541 gagaagctca cgcagtcggt gctgatgaag gtggagcggg agatcgcat cctgaagctc
 601 attgagcacc cccagctcct aaagctgcac gacgtttatg aaaacaaaaa atatttgtac
 661 ctggtgctag aacacgtgct aggtggtgag ctcttcgact acctggtgaa gaaggggagg
 721 ctgacgccta aggaggtcgg gaagtctctc cggcagatca tctctgcgct ggacttctgc
 781 cacagocact ccatatgcca cagggatctg aaacctgaaa acctcctgct ggacgagaag
 841 aacaacatcc gcacgcaga ctttgcatg gcgtccctgc aggttggcga cagcctgttg
 901 gagaccagct gtgggtcccc ccactacgcc tgccccgagg tgatccgggg ggagaagtat

-continued

961 gacggccgga aggcggacgt gtggagctgc ggcgtcatcc tgttcgcctt gctgggtggg
1021 gctctgccct tcgacgatga caacttgca cagctgctgg agaagtgaa gcggggcgtg
1081 ttccacatgc cgcactttat cccgcccac tgccagagtc tgctacgggg catgagcag
1141 gtggacgccg caccgcgcct caccgtagag cacatteaga aacacatatg gtatatagg
1201 ggcaagaatg agccgaacc agagcagccc attcctcgca aggtgcagat ccgctcgctg
1261 ccagccttg aggacatcga ccccgacgtg ctggacagca tgcactcact gggctgcttc
1321 cgagaccgca acaagctgct gcaggacctg ctgtccgagg aggagaacca ggagaagatg
1381 atttacttcc tcctcctgga ccggaaagaa aggtaccga gccaggagga tgaggacctg
1441 cccccccgga acgagataga ccctccccg aagcgtgtgg actccccgat gctgaaccg
1501 caccgcaagc ggcgccaga acgcaaatcc atggaggtgc tcagcgtgac ggacggcggc
1561 tccccggtgc ctgcgcggcg ggccattgag atggcccagc acggccagag gtctcggtcc
1621 atcagcgtg cctcctcagg cctttccacc agccactca gcagccccg ggtgacctc
1681 caccctcac caagggcgag tccctcccc accccaagg ggacacctgt ccacacgcca
1741 aaggagagcc cggctggcac gcccaacccc acgccccgt ccagccccag cgtcggagg
1801 gtgcccgtga ggcgcggct caactccatc aagaacagct ttctgggtcc accccgttc
1861 caccgcccga aactgcaagt tccgacgccc gaggagatgt ccaacctgac accagagtcg
1921 tccccagagc tggcgaagaa gtctcggttt gggaacttca tcagcctgga gaaggaggag
1981 cagatcttgc tggatcatca agacaaacct ctgagctcca tcaaggctga catcgtgac
2041 gccttctgt cgattcccag tctcagccc agcgtcatct cccaaacgag ctccgggccc
2101 gagtacaagg ccacggggg gccagccgtg ttccagaagc cggtaagtt ccaggttgat
2161 atcacctaca cggagggtgg ggaggcgcag aaggagaacg gcactactc cgtcaccttc
2221 accctgctct caggccccag ccgtcgcttc aagagggtgg tggagaccat ccaggcccag
2281 ctgctgagca cacacgccc gcctgcggcc cagcacttgt cagacaccac taactgtatg
2341 gaaatgatga cggggcggtt ttccaaatgt ggaattatcc cgaaggtta acatgtcac
2401 tccacgagc catcctctgt gaccgaagc agctgctgcg gacccgcctt cctccgctc
2461 ctgctgttgc tgccgggcag tgaggcccag ccagcgcctt cgtccacccc gcggcagctc
2521 ctgcctcag ctccgcacgg ccctgggag gaaggccagg ctgggggag cctcctccag
2581 cccggccgac ccgactccc ggtcacctga cccctcagca agaacagctt gcctggtggc
2641 cttctggggc caggaccccc ggtgggcaac gtagccacag gaacaggccc cgtccaccgc
2701 ctccacgccc cactggagg cctcctgcag gcccggtccc cgcctccctg gccgcgcgc
2761 ctccgtgtat tcttgccctc ctccaggtgc ctcccgctt ctgctctcac ccgcgcctcc
2821 cttgcctcat ctggggaggc tgtgggtctt ggcgtctctc tctggtgag gtggaaacag
2881 agacacctg cggcaccaga gccttcccag caggccaggc cgtggggtg ggatcagtgt
2941 tattttattt ccgttttcca atttatggat tctccgcacc tctgttcagg gaaggcggc
3001 ggccacatcc cctgccgtct gcgtgtctca ggcagtggg gggctggggc cagggcgcc
3061 tctgaggaca gagctgggtg ggcgcggggg ggtggcgag ctactgtaaa ctttaaa

REFERENCES

- [0082] 1. Zimmet, P., et al. (2001) *Nature* 414:782-787.
- [0083] 2. MacDonald, et al. (2005) *Philosophical Transactions of the Royal Society of London—Series B: Biological Sciences* 360:2211-2225.
- [0084] 3. Kasuga, M. (2006) *Journal of Clinical Investigation* 116:1756-1760.
- [0085] 4. Prentki, M., et al. (2006) *Journal of Clinical Investigation* 116:1802-1812.
- [0086] 5. Poitout, V., et al. (2002) *Endocrinology* 143:339-342.
- [0087] 6. Weyer, C., et al. (1999) *Journal of Clinical Investigation* 104:787-794.
- [0088] 7. Leahy, J. L. (2005) *Arch Med Res* 36:197-209.
- [0089] 8. Butler, A. E., et al. (2003) *Diabetes* 52:102-110.
- [0090] 9. Rhodes, C. J. (2005) *Science* 307:380-384.
- [0091] 10. Efanova, I. B., et al. (1998) *Journal of Biological Chemistry* 273:33501-33507.
- [0092] 11. Maedler, K., et al. (2005) *Journal of Clinical Endocrinology & Metabolism* 90:501-506.
- [0093] 12. Baggio, L. L., et al. (2006) *Annual Review of Medicine* 57:265-281.
- [0094] 13. Mari, A., et al. (2006) *Hormone & Metabolic Research* 38:838-844.
- [0095] 14. Kendall, D. M., et al. (2005) *Diabetes Care* 28:1083-1091.
- [0096] 15. Kolterman, O. G., et al. (2005) *American Journal of Health-System Pharmacy* 62:173-181.
- [0097] 16. Drucker, D. J. (2006) *Cell Metabolism* 3:153-165.
- [0098] 17. Mizuta, M., et al. (1997) *Diabetes* 46:2002-2006.
- [0099] 18. Miura, K., et al. (1998) 11p15.5. *Journal of Human Genetics* 43:283-284.
- [0100] 19. Stanchi, F., et al. (2001) *Yeast* 18:69-80.
- [0101] 20. Wang, Y., et al. (2000) *Journal of Biological Chemistry* 275:20033-20044.
- [0102] 21. Kashima, Y., et al. (2001) *Journal of Biological Chemistry* 276:46046-46053.
- [0103] 22. Nevins, A. K., et al. (2005) *Journal of Biological Chemistry* 280:1944-1952.
- [0104] 23. Oak S. et al., (2008) *Proc Natl Acad Sci USA*, April 8; 105(14): 5471-6.
- [0105] 24. Vainshtein I. et al., (2002) *J. Biomol Screen*. December; 7(6):507-14.
- [0106] 25. Miyazaki J. et al, (1990) *Endocrinology* 127: 126-132.
- [0107] Any patents or publications mentioned in this specification are incorporated herein by reference to the same extent as if each individual publication is specifically and individually indicated to be incorporated by reference. Amino acid and nucleic acid sequences for PBK1 are shown in appended pages marked "Appendix" which are considered part of this application and which are incorporated herein by reference in their entirety. Additionally U.S. Patent Application Publications 2003/0092036 and 2005/0125852 are incorporated herein by reference in their entirety.
- [0108] The compositions and methods described herein are presently representative of preferred embodiments, exemplary, and not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art. Such changes and other uses can be made without departing from the scope of the invention as set forth in the claims. All numerical ranges described herein include all integers and decimal values within the range and are also inclusive of the endpoints.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 19

<210> SEQ ID NO 1

<211> LENGTH: 3506

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```

gctgttcggc tcagctgcac ggctcggctc ggctcggctc ggctcggctg cgcgccgct 60
gacggcgctg cgctgggggc gcgggcgcg gggcgcgggc ctcgcgcgcg gcggcgcgcg 120
cgcgggcgga agccaggctc ccccgccgc cctgtcctct cgacgaggcg gaggcgctgc 180
cgcgggccag gcctcggact gccgcgtcgg agtggacgcg gggggcgcg gcgcggcgcg 240
acgcggggcg cgcaagcag cggggccgc gggggcgccc cgccgggtc ggcgcggacg 300
gcactcggcg gacgcggggc gacgtgggc gggccctccc tgcccgcgcg ccggggcgcc 360
cctggccggc gccggggccc agagcgatga catcgacggg gaaggacggc ggcgcgcagc 420
acgcgcagta tgttgggccc taccggctgg agaagacgct gggcaaggcg cagacaggtc 480
tggtgaagct ggggggtcac tcgctcacct gccagaaggt ggccatcaag atcgtaacc 540
gtgagaagct cagcgagtcg gtgctgatga aggtggagcg ggagatcgcg atcctgaagc 600
tcattgagca cccccagtc ctaaagctgc acgacgttta tgaaaacaaa aaatatttgt 660

```

-continued

acctgggtgct agaacacgtg tcaggtgggtg agctcttcga ctacctgggtg aagaagggga	720
ggctgacgcc taaggagggt cggaaagttct tccggcagat catctctgcg ctggacttct	780
gccacagcca ctccatattgc cacagggatc tgaacctga aaacctctcg ctggacgaga	840
agaacaacat ccgcatcgca gactttggca tggcgteect gcaggttggc gacagcctgt	900
tggagaccag ctgtgggtcc cccactacg cctgccccga ggtgatccgg ggggagaagt	960
atgacggcgg gaaggcggac gtgtggagct gcggcgatcat cctgttcgcc ttgctgggtg	1020
gggctctgcc cttecgacat gacaacttcg gacagctgct ggagaagggtg aagcggggcg	1080
tgttccacat gccgcacttt atcccggccg actgccagag tctgtacgg ggcatgatcg	1140
aggtggacgc cgcacgccgc ctacagctag agcacattca gaaacacata tggatatatg	1200
ggggcaagaa tgagccgaa ccagagcagc ccattcctcg caaggtgcag atccgctcgc	1260
tgcccagcct ggaggacatc gaccccgacg tgcctggacg catgcactca ctgggctgct	1320
tccgagaccg caacaagctg ctgcaggacc tgctgtccga ggaggagaac caggagaaga	1380
tgatttactt cctcctcctg gaccggaaa aaaggtaccc gagccaggag gatgaggacc	1440
tgccccccg gaacagata gacctcccc ggaagcgtgt ggactcccc atgtgaacc	1500
ggcacggcaa gcggcgccca gaacgcaaat ccatggaggt gctcagcgtg acggacggcg	1560
gctccccggt gcctgcggcg ggggccattg agatggccca gcacggccag aggtctcggg	1620
ccatcagcgg tgctctctca ggcctttcca ccagccact cagcagcccc cgggtgaccc	1680
ctcaccctc accaaggggc agtcccctcc ccaccccaa ggggacacct gtccacacgc	1740
caaaggagag cccggctggc acgcccaccc ccacgcccc gtccagcccc agcgtcggag	1800
gggtgcctcg gagggcgcg ctcaactcca tcaagaacag ctttctgggc tcaccccgct	1860
tccaccgcgg gaaactgcaa gttccgacgc cggaggagat gtccaacctg acaccagagt	1920
cgtccccaga gctggcgaag aagtccgtgt ttgggaactt catcagcctg gagaaggagg	1980
agcagatctt cgtggtcac aaagacaaac ctctgagctc catcaagggt gacatcgtgc	2040
acgccttctc gtgcattccc agtctcagcc acagcgtcat ctccaaaacg agcttcgggg	2100
ccgagtacaa ggccacgggg gggccagccg tgttcagaa gccggtcaag ttccagggtg	2160
atatcaccta cacggagggt ggggagcgcc agaaggagaa cggcatctac tccgtcacct	2220
tcacccgtct ctacggcccc agcgtcgtct tcaagagggt ggtggagacc atccaggccc	2280
agctgctgag cacacacgac ccgcctgcgg ccagcactt gtcagacacc actaactgta	2340
tggaaatgat gacggggcg ctttccaaat gtggaattat ccgaaaagt taacatgtca	2400
cctccacgag gccatcctct gtgaccgaag gcagctgctg cggacccgcc ctccctccgc	2460
tcctgtgtgt gctgcggggc agtgaggccc agcccagcgc cccgtccacc ccgcgcgacg	2520
tcctgcctc agctccgcac ggcccgtagg aggaaggcca ggctcggggg agcctctctc	2580
agcccgccg acccggactc ccggtcacct gacctctcag caagaacagc ctgcctggtg	2640
gccttctggg gccaggaccc ctggtgggca acgtagccac aggaacaggc cccgtccacc	2700
gcctccacgc cgcacctgga ggctcctcgc caggcccggt ccccgctctc ctggctgcgc	2760
cgcctccgtg tagtcttggc ctctcaggc tgctcccggt cctctcgtct caccgcgcgc	2820
tcccttgctt catctggggc ggctgtgggc tctggcgctc ctctctgggt gaggtggaaa	2880
cagagacacc ctgcggcacc agagccttcc cagcaggcca ggccgctggg ctgggatcag	2940

-continued

```

tggtatttat ttgccgtttt aatttatgga ttctccgcac ctctgttcag ggaagggcgg 3000
cgccacatc ccctgccgtc tgcgtgtctc aggcagtggg ggggctgggg ccagggcgcc 3060
ctctgaggac agagctggtg gggcgcgggg gggtggcga gctactgtaa actttaaga 3120
attcctgcaa gatattttta taaacttttt ttcttggtg gtttttgaa aaggggtgtg 3180
gggtgggggc gccgctgggg cagggccagg ttttgtgtt tagtcccttg ctctgcttc 3240
tttctacaca cacatctaaa gacgggtcgg ctgcgtctgt catgggttcc gtctctctgt 3300
ggagaagcag ctccacctct gggggggctc ggggcagagg ggcggtgtct cgtagcgggc 3360
ggcagcgcca gcgccctct gtcaggctgg ggcaatcttg gttttgtgtc caaaggtgaa 3420
ggggtaggag gagggccctc agctggccct cccacacac aggacggcag gggcactgtg 3480
aggcttttct tattaataatg aaaaaa 3506

```

<210> SEQ ID NO 2

<211> LENGTH: 668

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

```

Met Thr Ser Thr Gly Lys Asp Gly Gly Ala Gln His Ala Gln Tyr Val
1           5           10           15
Gly Pro Tyr Arg Leu Glu Lys Thr Leu Gly Lys Gly Gln Thr Gly Leu
20          25          30
Val Lys Leu Gly Val His Cys Val Thr Cys Gln Lys Val Ala Ile Lys
35          40          45
Ile Val Asn Arg Glu Lys Leu Ser Glu Ser Val Leu Met Lys Val Glu
50          55          60
Arg Glu Ile Ala Ile Leu Lys Leu Ile Glu His Pro His Val Leu Lys
65          70          75          80
Leu His Asp Val Tyr Glu Asn Lys Lys Tyr Leu Tyr Leu Val Leu Glu
85          90          95
His Val Ser Gly Gly Glu Leu Phe Asp Tyr Leu Val Lys Lys Gly Arg
100         105         110
Leu Thr Pro Lys Glu Ala Arg Lys Phe Phe Arg Gln Ile Ile Ser Ala
115         120         125
Leu Asp Phe Cys His Ser His Ser Ile Cys His Arg Asp Leu Lys Pro
130         135         140
Glu Asn Leu Leu Leu Asp Glu Lys Asn Asn Ile Arg Ile Ala Asp Phe
145         150         155         160
Gly Met Ala Ser Leu Gln Val Gly Asp Ser Leu Leu Glu Thr Ser Cys
165         170         175
Gly Ser Pro His Tyr Ala Cys Pro Glu Val Ile Arg Gly Glu Lys Tyr
180         185         190
Asp Gly Arg Lys Ala Asp Val Trp Ser Cys Gly Val Ile Leu Phe Ala
195         200         205
Leu Leu Val Gly Ala Leu Pro Phe Asp Asp Asp Asn Leu Arg Gln Leu
210         215         220
Leu Glu Lys Val Lys Arg Gly Val Phe His Met Pro His Phe Ile Pro
225         230         235         240
Pro Asp Cys Gln Ser Leu Leu Arg Gly Met Ile Glu Val Asp Ala Ala
245         250         255

```

Arg	Arg	Leu	Thr	Leu	Glu	His	Ile	Gln	Lys	His	Ile	Trp	Tyr	Ile	Gly	
			260							265				270		
Gly	Lys	Asn	Glu	Pro	Glu	Pro	Glu	Gln	Pro	Ile	Pro	Arg	Lys	Val	Gln	
			275							280				285		
Ile	Arg	Ser	Leu	Pro	Ser	Leu	Glu	Asp	Ile	Asp	Pro	Asp	Val	Leu	Asp	
			290							295				300		
Ser	Met	His	Ser	Leu	Gly	Cys	Phe	Arg	Asp	Arg	Asn	Lys	Leu	Leu	Gln	
			305							310				315		
Asp	Leu	Leu	Ser	Glu	Glu	Asn	Gln	Glu	Lys	Met	Ile	Tyr	Phe	Leu		
			325							330				335		
Leu	Leu	Asp	Arg	Lys	Glu	Arg	Tyr	Pro	Ser	Gln	Glu	Asp	Glu	Asp	Leu	
			340							345				350		
Pro	Pro	Arg	Asn	Glu	Ile	Asp	Pro	Pro	Arg	Lys	Arg	Val	Asp	Ser	Pro	
			355							360				365		
Met	Leu	Asn	Arg	His	Gly	Lys	Arg	Arg	Pro	Glu	Arg	Lys	Ser	Met	Glu	
			370							375				380		
Val	Leu	Ser	Val	Thr	Asp	Gly	Gly	Ser	Pro	Val	Pro	Ala	Arg	Arg	Ala	
			385							390				395		
Ile	Glu	Met	Ala	Gln	His	Gly	Gln	Arg	Ser	Arg	Ser	Ile	Ser	Gly	Ala	
			405							410				415		
Ser	Ser	Gly	Leu	Ser	Thr	Ser	Pro	Leu	Ser	Ser	Pro	Arg	Val	Thr	Pro	
			420							425				430		
His	Pro	Ser	Pro	Arg	Gly	Ser	Pro	Leu	Pro	Thr	Pro	Lys	Gly	Thr	Pro	
			435							440				445		
Val	His	Thr	Pro	Lys	Glu	Ser	Pro	Ala	Gly	Thr	Pro	Asn	Pro	Thr	Pro	
			450							455				460		
Pro	Ser	Ser	Pro	Ser	Val	Gly	Gly	Val	Pro	Trp	Arg	Ala	Arg	Leu	Asn	
			465							470				475		
Ser	Ile	Lys	Asn	Ser	Phe	Leu	Gly	Ser	Pro	Arg	Phe	His	Arg	Arg	Lys	
			485							490				495		
Leu	Gln	Val	Pro	Thr	Pro	Glu	Glu	Met	Ser	Asn	Leu	Thr	Pro	Glu	Ser	
			500							505				510		
Ser	Pro	Glu	Leu	Ala	Lys	Lys	Ser	Trp	Phe	Gly	Asn	Phe	Ile	Ser	Leu	
			515							520				525		
Glu	Lys	Glu	Glu	Gln	Ile	Phe	Val	Val	Ile	Lys	Asp	Lys	Pro	Leu	Ser	
			530							535				540		
Ser	Ile	Lys	Ala	Asp	Ile	Val	His	Ala	Phe	Leu	Ser	Ile	Pro	Ser	Leu	
			545							550				555		
Ser	His	Ser	Val	Ile	Ser	Gln	Thr	Ser	Phe	Arg	Ala	Glu	Tyr	Lys	Ala	
			565							570				575		
Thr	Gly	Gly	Pro	Ala	Val	Phe	Gln	Lys	Pro	Val	Lys	Phe	Gln	Val	Asp	
			580							585				590		
Ile	Thr	Tyr	Thr	Glu	Gly	Gly	Glu	Ala	Gln	Lys	Glu	Asn	Gly	Ile	Tyr	
			595							600				605		
Ser	Val	Thr	Phe	Thr	Leu	Leu	Ser	Gly	Pro	Ser	Arg	Arg	Phe	Lys	Arg	
			610							615				620		
Val	Val	Glu	Thr	Ile	Gln	Ala	Gln	Leu	Leu	Ser	Thr	His	Asp	Pro	Pro	
			625							630				635		
Ala	Ala	Gln	His	Leu	Ser	Asp	Thr	Thr	Asn	Cys	Met	Glu	Met	Met	Thr	

-continued

Gly Arg Leu Ser Lys Cys Gly Ile Ile Pro Lys Ser
660 665

<210> SEQ ID NO 3
<211> LENGTH: 3109
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

gggggcccgc cagaaacggg ctggggaggg ggggccccgc agccccctg ggccatgctg 60
actccccggg cctgaccccc ccgggccagc cccccctccc ccagctccgc ggccccccga 120
ctgggggggg ccagcccagc cccctgggga cccccggaga ggtggggggc agccgggggg 180
gccgggacgg agcggtcggc ggccccacc ggagagacgg ggcgacggcc gcaggggggg 240
cggccggggg accggtcggg ccgggaccaa gggcaccatg tcgtccgggg ccaaggaggg 300
aggtgggggc tctcccgct accacctccc ccacccccac cccacccac cccagcacgc 360
ccaatatgtg ggccccctac ggctggagaa gacgctgggc aaaggacaga cagggtgtgt 420
taaactcggg gtccactgca tcacgggtca gaaggtcgcc atcaagatcg tgaaccggga 480
gaagctgtcg gagtcgggct tgatgaaggc ggagcgggag atcgccatcc tgaagctcat 540
cgaacaccca catgtctca agctccacga cgtctacgag aacaagaaat atttgtacct 600
ggttctggag cactgtctcg ggggtgagct attcgactac ctggtaaaga aggggagact 660
gacgccaag gaggcccgaa agttcttcgc ccagattgtg tctgcgctgg acttctgcca 720
cagctactcc atctgccaca gagacctaaa gcccgagaac ctgcttttgg atgagaaaaa 780
caacatccgc attgcagact tcggcatggc gtccctgcag gtgggggaca gcctcctgga 840
gaccagctgc ggggtccccc attatgcgtg tcagagggtg attaaggggg aaaaatatga 900
tgggccggcg gcagacatgt ggagctgtgg agtcatectc ttgcacctgc tcgtgggggc 960
tctgcccttt gatgacgaca acctccgcca gctgctggag aaggtgaaac ggggctcttt 1020
ccacatgccc cacttcatcc ctccagattg ccagagcctc ctgaggggaa tgatcgaagt 1080
ggagcccgaa aaaaggctca gtctggagca aattcagaaa catccttggc acctaggcgg 1140
gaaacacgag ccagaccgct gcctggagcc agccctggc cgccgggtag ccatgcggag 1200
cctgccatcc aacggagagc tggacccgca cgtcctagag agcatggcat cactgggctg 1260
cttcagggac cgcgagaggc tgcacgcga gctgcgcagt gaggaggaga accaagaaaa 1320
gatgatatat tatctgcttt tggatcgga ggagcgggat ccagctgtg aggaccagga 1380
cctgcctccc cggaatgatg ttgaccccc ccggaagcgt gtggattctc ccatgctgag 1440
ccgtcacggg aagcggcgac cagagcggaa gtccatggaa gtctgagca tcaccgatgc 1500
cgggggtggg ggtccctctg tacccacccg acgggccttg gagatggccc agcacagcca 1560
gagatcccg agcgtcagtg gagcctccac gggctgtgct tcagccctc taagcagccc 1620
aaggagtccg gtcttttctt ttccaccgga gccgggggct ggagatgagg ctcgaggcgg 1680
gggctccccg acttccaaaa cgcagacgct gccttctcgg gggccaggg gtggggggcg 1740
cggggagcag cccccgccc ccagtgccc ctccacccc ctgcccggcc cccaggtc 1800
cccgcgtcc tctggcggga ccccttgca ctgcctctg cacacgccc gggccagtcc 1860
cacggggacc ccggggacaa caccacccc cagccccggc ggtggcgtcg ggggagccgc 1920
ctgaggaggt cgtctcaact ccacccgcaa cagcttctg ggtccctc gcttaccg 1980

-continued

```

gcgcaagatg caggtecccta ccgctgagga gatgtccagc ttgacgccag agtcctcccc 2040
ggagctggca aaacgtctct gggtcgggaa cttcatctcc ttggacaaag aagaacaaat 2100
attcctcgtg ctaaaggaca aacctctcag cagcatcaaa gcagacatcg tccatgcctt 2160
tctgtcgatc ccagacctga gtcacagtgt gctgtcacag accagcttca gggccgagta 2220
caaggccagt ggcggcccct ccgtcttcca aaagcccgtc cgcttccagg tggacatcag 2280
ctcctctgag ggtccagagc cctccccgcg acgggacggc agcggagggtg gtggcatcta 2340
ctccgtcacc ttcactetca tctcgggtcc cagccgtcgg ttcaagcgag tggtgagagc 2400
catccaggca cagctcctga gcactcatga ccagccctcc gtgcaggccc tggcagacga 2460
gaagaacggg gccagacccc ggctgtctgg tccccacccc cgaagcctgc agccccacc 2520
cggcgcacca gaccagagac tgagcagatc tccccgccga ggccccccca aggacaagaa 2580
gctcctggcc accaacggga cccctctgcc ctgaccccac ggggccgggg agggagggga 2640
ccccctcca ccccccttcc gtgccccca actgtgaatc tgtaaataag gccaaggaa 2700
catgtcggga ggggggtgga cacaaaaacc ggcttgcctc tgcagggatg gggctccaca 2760
ggcgtgcccc aactgggggt gggtctaggg gaacaggggg cgggggagct gtttctattt 2820
tatttattga ttaatttatt attttattta ttgatcaatc tctctgcggg gtggggtggg 2880
ggagggacgg gagctgggtg ggggtggctta gcagatccgg acagggccct ctgtccctgt 2940
gtcgtcccca acccctctt cccgggcccc tcctccctcg gtccctcccc cagcaccttc 3000
tgtagcgatt tgtctccgg aaggaattct ggttctcgct gatcctgctt gcgtccgtgt 3060
ctctgattcc gccggcggca aaaaaaaaa aaaaaaaaa aaaaaaaaa 3109

```

<210> SEQ ID NO 4

<211> LENGTH: 778

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

```

Met Ser Ser Gly Ala Lys Glu Gly Gly Gly Ser Pro Ala Tyr His
1      5      10      15
Leu Pro His Pro His Pro His Pro Gln His Ala Gln Tyr Val Gly
20     25     30
Pro Tyr Arg Leu Glu Lys Thr Leu Gly Lys Gly Gln Thr Gly Leu Val
35     40     45
Lys Leu Gly Val His Cys Ile Thr Gly Gln Lys Val Ala Ile Lys Ile
50     55     60
Val Asn Arg Glu Lys Leu Ser Glu Ser Val Leu Met Lys Val Glu Arg
65     70     75     80
Glu Ile Ala Ile Leu Lys Leu Ile Glu His Pro His Val Leu Lys Leu
85     90     95
His Asp Val Tyr Glu Asn Lys Lys Tyr Leu Tyr Leu Val Leu Glu His
100    105    110
Val Ser Gly Gly Glu Leu Phe Asp Tyr Leu Val Lys Lys Gly Arg Leu
115    120    125
Thr Pro Lys Glu Ala Arg Lys Phe Phe Arg Gln Ile Val Ser Ala Leu
130    135    140
Asp Phe Cys His Ser Tyr Ser Ile Cys His Arg Asp Leu Lys Pro Glu
145    150    155    160

```

-continued

Asn	Leu	Leu	Leu	Asp	Glu	Lys	Asn	Asn	Ile	Arg	Ile	Ala	Asp	Phe	Gly	165	170	175
Met	Ala	Ser	Leu	Gln	Val	Gly	Asp	Ser	Leu	Leu	Glu	Thr	Ser	Cys	Gly	180	185	190
Ser	Pro	His	Tyr	Ala	Cys	Pro	Glu	Val	Ile	Lys	Gly	Glu	Lys	Tyr	Asp	195	200	205
Gly	Arg	Arg	Ala	Asp	Met	Trp	Ser	Cys	Gly	Val	Ile	Leu	Phe	Ala	Leu	210	215	220
Leu	Val	Gly	Ala	Leu	Pro	Phe	Asp	Asp	Asp	Asn	Leu	Arg	Gln	Leu	Leu	225	230	235
Glu	Lys	Val	Lys	Arg	Gly	Val	Phe	His	Met	Pro	His	Phe	Ile	Pro	Pro	245	250	255
Asp	Cys	Gln	Ser	Leu	Leu	Arg	Gly	Met	Ile	Glu	Val	Glu	Pro	Glu	Lys	260	265	270
Arg	Leu	Ser	Leu	Glu	Gln	Ile	Gln	Lys	His	Pro	Trp	Tyr	Leu	Gly	Gly	275	280	285
Lys	His	Glu	Pro	Asp	Pro	Cys	Leu	Glu	Pro	Ala	Pro	Gly	Arg	Arg	Val	290	295	300
Ala	Met	Arg	Ser	Leu	Pro	Ser	Asn	Gly	Glu	Leu	Asp	Pro	Asp	Val	Leu	305	310	315
Glu	Ser	Met	Ala	Ser	Leu	Gly	Cys	Phe	Arg	Asp	Arg	Glu	Arg	Leu	His	325	330	335
Arg	Glu	Leu	Arg	Ser	Glu	Glu	Glu	Asn	Gln	Glu	Lys	Met	Ile	Tyr	Tyr	340	345	350
Leu	Leu	Leu	Asp	Arg	Lys	Glu	Arg	Tyr	Pro	Ser	Cys	Glu	Asp	Gln	Asp	355	360	365
Leu	Pro	Pro	Arg	Asn	Asp	Val	Asp	Pro	Pro	Arg	Lys	Arg	Val	Asp	Ser	370	375	380
Pro	Met	Leu	Ser	Arg	His	Gly	Lys	Arg	Arg	Pro	Glu	Arg	Lys	Ser	Met	385	390	395
Glu	Val	Leu	Ser	Ile	Thr	Asp	Ala	Gly	Gly	Gly	Gly	Ser	Pro	Val	Pro	405	410	415
Thr	Arg	Arg	Ala	Leu	Glu	Met	Ala	Gln	His	Ser	Gln	Arg	Ser	Arg	Ser	420	425	430
Val	Ser	Gly	Ala	Ser	Thr	Gly	Leu	Ser	Ser	Ser	Pro	Leu	Ser	Ser	Pro	435	440	445
Arg	Ser	Pro	Val	Phe	Ser	Phe	Ser	Pro	Glu	Pro	Gly	Ala	Gly	Asp	Glu	450	455	460
Ala	Arg	Gly	Gly	Gly	Ser	Pro	Thr	Ser	Lys	Thr	Gln	Thr	Leu	Pro	Ser	465	470	475
Arg	Gly	Pro	Arg	Gly	Gly	Gly	Ala	Gly	Glu	Gln	Pro	Pro	Pro	Pro	Ser	485	490	495
Ala	Arg	Ser	Thr	Pro	Leu	Pro	Gly	Pro	Pro	Gly	Ser	Pro	Arg	Ser	Ser	500	505	510
Gly	Gly	Thr	Pro	Leu	His	Ser	Pro	Leu	His	Thr	Pro	Arg	Ala	Ser	Pro	515	520	525
Thr	Gly	Thr	Pro	Gly	Thr	Thr	Pro	Pro	Pro	Ser	Pro	Gly	Gly	Gly	Val	530	535	540
Gly	Gly	Ala	Ala	Trp	Arg	Ser	Arg	Leu	Asn	Ser	Ile	Arg	Asn	Ser	Phe	545	550	555

-continued

Leu	Gly	Ser	Pro	Arg	Phe	His	Arg	Arg	Lys	Met	Gln	Val	Pro	Thr	Ala
				565					570					575	
Glu	Glu	Met	Ser	Ser	Leu	Thr	Pro	Glu	Ser	Ser	Pro	Glu	Leu	Ala	Lys
			580					585					590		
Arg	Ser	Trp	Phe	Gly	Asn	Phe	Ile	Ser	Leu	Asp	Lys	Glu	Glu	Gln	Ile
		595					600					605			
Phe	Leu	Val	Leu	Lys	Asp	Lys	Pro	Leu	Ser	Ser	Ile	Lys	Ala	Asp	Ile
	610					615					620				
Val	His	Ala	Phe	Leu	Ser	Ile	Pro	Ser	Leu	Ser	His	Ser	Val	Leu	Ser
	625				630					635					640
Gln	Thr	Ser	Phe	Arg	Ala	Glu	Tyr	Lys	Ala	Ser	Gly	Gly	Pro	Ser	Val
				645					650					655	
Phe	Gln	Lys	Pro	Val	Arg	Phe	Gln	Val	Asp	Ile	Ser	Ser	Ser	Glu	Gly
			660					665					670		
Pro	Glu	Pro	Ser	Pro	Arg	Arg	Asp	Gly	Ser	Gly	Gly	Gly	Gly	Ile	Tyr
		675					680					685			
Ser	Val	Thr	Phe	Thr	Leu	Ile	Ser	Gly	Pro	Ser	Arg	Arg	Phe	Lys	Arg
	690					695					700				
Val	Val	Glu	Thr	Ile	Gln	Ala	Gln	Leu	Leu	Ser	Thr	His	Asp	Gln	Pro
	705				710					715					720
Ser	Val	Gln	Ala	Leu	Ala	Asp	Glu	Lys	Asn	Gly	Ala	Gln	Thr	Arg	Pro
			725						730					735	
Ala	Gly	Ala	Pro	Pro	Arg	Ser	Leu	Gln	Pro	Pro	Pro	Gly	Arg	Pro	Asp
			740					745					750		
Pro	Glu	Leu	Ser	Ser	Ser	Pro	Arg	Arg	Gly	Pro	Pro	Lys	Asp	Lys	Lys
		755					760					765			
Leu	Leu	Ala	Thr	Asn	Gly	Thr	Pro	Leu	Pro						
	770					775									

<210> SEQ ID NO 5

<211> LENGTH: 3576

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

agtctcaggc	tggtctagttc	ctccttcctg	gtcactgagc	cagccttgct	gaggggagag	60
cgggttcttg	acgtgctctg	agcttccttc	ctcacagcct	tgtcctggg	ccagatcagc	120
aggaaagcag	ccagtgcctc	gccatggcct	gcccgggtgg	ggctcctgaag	ctggggcccg	180
agcagggggc	acagttctgc	cccacatggc	cctagtttgg	ggagggagcc	tggtagggca	240
ccagcctcac	cccatgagcc	ctgagggcca	ccccagccga	tgggcacgtc	cccgcgggcc	300
ctgcatctgt	ccttcctccc	tctgctcccc	aagagagccc	aggtctggcc	cagcgtgggg	360
caggggaggg	gccgcacatc	acagagtggc	agctggccac	actccgggcc	cacagctgct	420
ccagccgcac	ctccaccttc	ctcaaggcca	gacctgggtc	tgcctgcagc	ccagcccagc	480
aggtctggtg	aagctggggg	ttcactgcgt	cacctgccag	aaggtggcca	tcaagatcgt	540
caaccgtgag	aagctcagcg	agtcggtgct	gatgaagggtg	gagcgggaga	tcgcatcct	600
gaagctcatt	gagcaccccc	acgtcctaaa	gctgcacgac	gtttatgaaa	acaaaaata	660
tttgtacctg	gtgctagaac	acgtgtcagg	tggtgagctc	ttcgactacc	tggtgaagaa	720
ggggaggctg	acgcctaagg	aggtcgggaa	gttcttcctg	cagatcatct	ctgcgctgga	780

-continued

cttctgccac agccactcca tatgccacag ggaatctgaaa cctgaaaacc tctgtctgga	840
cgagaagaac aacatccgca tcgcagactt tggcatggcg tccctgcagg ttggcgacag	900
cctgttgagg accagctgtg ggtcccccca ctacgcctgc cccgaggtga tccgggggga	960
gaagtatgac ggccggaagg cggacgtgtg gagetgcggc gtcactctgt tcgccttget	1020
ggtgggggct ctgcccctcg acgatgacaa cttgcgacag ctgctggaga aggtgaagcg	1080
gggctgttgc cacatgccgc actttatccc gcccactgc cagagtctgc tacggggcat	1140
gatcgagggtg gacgcgcac gccgcctcac gctagagcac attcagaaac acatatggta	1200
tatagggggc aagaatgagc ccgaaccaga gcagccatt cctcgcaagg tgcagatccg	1260
ctcgtgccc agcctggagg acatcgacc cgacgtgctg gacagcatgc actcactggg	1320
ctgcttcga gaccgcaaca agctgctgca ggacctgctg tccgaggagg agaaccagga	1380
gaagatgatt tacttctccc tcttgaccg gaaagaaagg taccgagcc aggaggatga	1440
ggacctgccc ccccggaac agatagacc tccccggaag cgtgtggact cccgatgct	1500
gaaccggcac ggcaagcggc gcccagaacg caaatccatg gaggtgctca gcgtgacgga	1560
cggcggtccc ccggtgcctg cgcggcgggc cattgagatg gccagcacg gccagaggtc	1620
tcggtccatc agcgtgctt cctcaggcct ttccaccagc cactcagca gccccgggt	1680
gacctctcac cctcaccaa gggcgagtc cctccccacc ccaagggga cactgtcca	1740
cacgccaag gagagcccg ctggcacgcc caacccacg ccccgctcca gccccagct	1800
cggaggggtg ccttgagggt cgcggctcaa ctccatcaag aacagcttcc tgggtcacc	1860
ccgcttcac cgcggaaac tgcaagttcc gacgcggag gagatgtcca acctgacacc	1920
agagtctcc ccagagctgg cgaagaagtc ctggtttggg aacttcatca gcttgagaa	1980
ggaggagcag atcttctgtg tcatcaaga caaacctctg agctccatca aggtgacat	2040
cgtgcacgcc ttctgtcga ttcccagtc cagccacagc gtcactccc aaacgagctt	2100
ccgggcccag tacaaggcca cggggggggc agcctgttcc cagaagccg tcaagtcca	2160
ggttgatata acctacagc aggggtggga ggcgagaag gagaacgga tctactcgt	2220
caccttcacc ctgctctcag gcccagccg tcgcttcaag aggggtgtgg agaccatcca	2280
ggcccagctg ctgagcacac acgaccgcc tgcggcccag cacttgcag acaccactaa	2340
ctgtatggaa atgatgacgg ggcggcttcc caaatgtgac gagaagaacg ggcaggcggc	2400
ccaggcccc agcaccccc ccaagcggag tgcccacggc cactcgggtg actccgccc	2460
cgtggccct ggcgccggag gggacgcga gtacccaacg ggcaaggaca cggccaagat	2520
gggcccgc accgcccgc gcgagcagc ttagacacac tagccccccc cccagcaca	2580
gcactgacag cggctgcctc gccgcccgc gccgcccctg ccccgagtgg acccgcgcc	2640
gcgcgcccgc tccgtccaga ctgttctcag agcctgggag gaaaggaaag gggcgttggg	2700
gccggcctgt gggctgcgcc acccgcccc gctctctttt ctctctgtct ctgcctctgc	2760
ctgtctctga cagcatcgt tgtttccact ctgataccag gaattatccc gaaaagttaa	2820
catgtcaact ccacgaggcc atcctctgtg accgaaggca gctgctgcgg acccgccctc	2880
cctccgctcc tgtgttgtc gccgggcagt gaggccagc ccagcgcccc gtccacccc	2940
cggcagctcc tcgcctcagc tccgcacggc ccgtgggagg aaggccaggc tcgggggagc	3000
ctcctccagc ccggccgacc cggactcccc gtcacctgac ccctcagcaa gaacagcctg	3060

-continued

```

cctgggtggcc ttctggggcc aggacccctg gtgggcaacg tagccacagg aacaggcccc 3120
gtccaccgcc tccacgccgc acctggaggc ctctctgcag gcccggtccc cgctccctg 3180
gccgcgccgc ctccgtgtag tcttgccctc ctccagctgc ctcccgctct ctgtctcac 3240
ccgcgcctcc ctgtctcat ctggggcggc tgtgggctct ggcgtctctc tctggctgag 3300
gtggaacacag agacaccctg cggcaccaga gccttcccag caggccaggc cgctgggctg 3360
ggatcagtgt tatttatctt ccgttttaat ttatggattc tccgcacctc tgttcaggga 3420
agggcgggcg ccacatcccc tgccgtctgc gtgtctcagg cagtgggggg gctggggcca 3480
gggcgcctcc tgaggacaga gctgggtggg cgcggggggg ctggcgagct actgtaaact 3540
ttaaagaatt cctgcaagat attttataa actttt 3576

```

<210> SEQ ID NO 6

<211> LENGTH: 766

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

```

Met Ser Pro Glu Gly His Pro Ser Arg Trp Ala Arg Pro Arg Arg Pro
1           5           10           15
Cys Ile Cys Pro Ser Ser Leu Cys Ser Pro Arg Glu Pro Arg Ser Gly
20          25          30
Pro Ala Val Gly Arg Gly Gly Ala Ala His His Arg Val Pro Ala Gly
35          40          45
His Thr Pro Gly Pro Gln Leu Leu Gln Pro His Leu His Leu Pro Gln
50          55          60
Gly Gln Thr Trp Leu Cys Leu Gln Pro Ser Pro Ala Gly Leu Val Lys
65          70          75          80
Leu Gly Val His Cys Val Thr Cys Gln Lys Val Ala Ile Lys Ile Val
85          90          95
Asn Arg Glu Lys Leu Ser Glu Ser Val Leu Met Lys Val Glu Arg Glu
100         105         110
Ile Ala Ile Leu Lys Leu Ile Glu His Pro His Val Leu Lys Leu His
115         120         125
Asp Val Tyr Glu Asn Lys Lys Tyr Leu Tyr Leu Val Leu Glu His Val
130         135         140
Ser Gly Gly Glu Leu Phe Asp Tyr Leu Val Lys Lys Gly Arg Leu Thr
145         150         155         160
Pro Lys Glu Ala Arg Lys Phe Phe Arg Gln Ile Ile Ser Ala Leu Asp
165         170         175
Phe Cys His Ser His Ser Ile Cys His Arg Asp Leu Lys Pro Glu Asn
180         185         190
Leu Leu Leu Asp Glu Lys Asn Asn Ile Arg Ile Ala Asp Phe Gly Met
195         200         205
Ala Ser Leu Gln Val Gly Asp Ser Leu Leu Glu Thr Ser Cys Gly Ser
210         215         220
Pro His Tyr Ala Cys Pro Glu Val Ile Arg Gly Glu Lys Tyr Asp Gly
225         230         235         240
Arg Lys Ala Asp Val Trp Ser Cys Gly Val Ile Leu Phe Ala Leu Leu
245         250         255
Val Gly Ala Leu Pro Phe Asp Asp Asp Asn Leu Arg Gln Leu Leu Glu
260         265         270

```

-continued

Lys	Val	Lys	Arg	Gly	Val	Phe	His	Met	Pro	His	Phe	Ile	Pro	Pro	Asp	275	280	285
Cys	Gln	Ser	Leu	Leu	Arg	Gly	Met	Ile	Glu	Val	Asp	Ala	Ala	Arg	Arg	290	295	300
Leu	Thr	Leu	Glu	His	Ile	Gln	Lys	His	Ile	Trp	Tyr	Ile	Gly	Gly	Lys	305	310	315
Asn	Glu	Pro	Glu	Pro	Glu	Gln	Pro	Ile	Pro	Arg	Lys	Val	Gln	Ile	Arg	325	330	335
Ser	Leu	Pro	Ser	Leu	Glu	Asp	Ile	Asp	Pro	Asp	Val	Leu	Asp	Ser	Met	340	345	350
His	Ser	Leu	Gly	Cys	Phe	Arg	Asp	Arg	Asn	Lys	Leu	Leu	Gln	Asp	Leu	355	360	365
Leu	Ser	Glu	Glu	Glu	Asn	Gln	Glu	Lys	Met	Ile	Tyr	Phe	Leu	Leu	Leu	370	375	380
Asp	Arg	Lys	Glu	Arg	Tyr	Pro	Ser	Gln	Glu	Asp	Glu	Asp	Leu	Pro	Pro	385	390	395
Arg	Asn	Glu	Ile	Asp	Pro	Pro	Arg	Lys	Arg	Val	Asp	Ser	Pro	Met	Leu	405	410	415
Asn	Arg	His	Gly	Lys	Arg	Arg	Pro	Glu	Arg	Lys	Ser	Met	Glu	Val	Leu	420	425	430
Ser	Val	Thr	Asp	Gly	Gly	Ser	Pro	Val	Pro	Ala	Arg	Arg	Ala	Ile	Glu	435	440	445
Met	Ala	Gln	His	Gly	Gln	Arg	Ser	Arg	Ser	Ile	Ser	Gly	Ala	Ser	Ser	450	455	460
Gly	Leu	Ser	Thr	Ser	Pro	Leu	Ser	Ser	Pro	Arg	Val	Thr	Pro	His	Pro	465	470	475
Ser	Pro	Arg	Gly	Ser	Pro	Leu	Pro	Thr	Pro	Lys	Gly	Thr	Pro	Val	His	485	490	495
Thr	Pro	Lys	Glu	Ser	Pro	Ala	Gly	Thr	Pro	Asn	Pro	Thr	Pro	Pro	Ser	500	505	510
Ser	Pro	Ser	Val	Gly	Gly	Val	Pro	Trp	Arg	Ala	Arg	Leu	Asn	Ser	Ile	515	520	525
Lys	Asn	Ser	Phe	Leu	Gly	Ser	Pro	Arg	Phe	His	Arg	Arg	Lys	Leu	Gln	530	535	540
Val	Pro	Thr	Pro	Glu	Glu	Met	Ser	Asn	Leu	Thr	Pro	Glu	Ser	Ser	Pro	545	550	555
Glu	Leu	Ala	Lys	Lys	Ser	Trp	Phe	Gly	Asn	Phe	Ile	Ser	Leu	Glu	Lys	565	570	575
Glu	Glu	Gln	Ile	Phe	Val	Val	Ile	Lys	Asp	Lys	Pro	Leu	Ser	Ser	Ile	580	585	590
Lys	Ala	Asp	Ile	Val	His	Ala	Phe	Leu	Ser	Ile	Pro	Ser	Leu	Ser	His	595	600	605
Ser	Val	Ile	Ser	Gln	Thr	Ser	Phe	Arg	Ala	Glu	Tyr	Lys	Ala	Thr	Gly	610	615	620
Gly	Pro	Ala	Val	Phe	Gln	Lys	Pro	Val	Lys	Phe	Gln	Val	Asp	Ile	Thr	625	630	635
Tyr	Thr	Glu	Gly	Gly	Glu	Ala	Gln	Lys	Glu	Asn	Gly	Ile	Tyr	Ser	Val	645	650	655
Thr	Phe	Thr	Leu	Leu	Ser	Gly	Pro	Ser	Arg	Arg	Phe	Lys	Arg	Val	Val	660	665	670

-continued

Glu Thr Ile Gln Ala Gln Leu Leu Ser Thr His Asp Pro Pro Ala Ala
 675 680 685
 Gln His Leu Ser Asp Thr Thr Asn Cys Met Glu Met Met Thr Gly Arg
 690 695 700
 Leu Ser Lys Cys Asp Glu Lys Asn Gly Gln Ala Ala Gln Ala Pro Ser
 705 710 715 720
 Thr Pro Ala Lys Arg Ser Ala His Gly Pro Leu Gly Asp Ser Ala Ala
 725 730 735
 Ala Gly Pro Gly Pro Gly Gly Asp Ala Glu Tyr Pro Thr Gly Lys Asp
 740 745 750
 Thr Ala Lys Met Gly Pro Pro Thr Ala Arg Arg Glu Gln Pro
 755 760 765

<210> SEQ ID NO 7
 <211> LENGTH: 23
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: DNA primer

<400> SEQUENCE: 7

cgatgacatc gacggggaag gac 23

<210> SEQ ID NO 8
 <211> LENGTH: 23
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: DNA primer

<400> SEQUENCE: 8

gatggcctcg tggaggtgac atg 23

<210> SEQ ID NO 9
 <211> LENGTH: 57
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: DNA primer

<400> SEQUENCE: 9

gccaccatgg attacaagga tgacgacgat aagacatcga cggggaagga cggcggc 57

<210> SEQ ID NO 10
 <211> LENGTH: 23
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: DNA primer

<400> SEQUENCE: 10

gatggcctcg tggaggtgac atg 23

<210> SEQ ID NO 11
 <211> LENGTH: 34
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: DNA primer

<400> SEQUENCE: 11

-continued

ccagaagggtg gccatcatga tcgtcaaccg tgag 34

<210> SEQ ID NO 12
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: DNA primer

<400> SEQUENCE: 12

cgccgcacgc cgctcgcgc tagagcacat tcag 34

<210> SEQ ID NO 13
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: DNA primer

<400> SEQUENCE: 13

gtcacctgac ccctcagcaa 20

<210> SEQ ID NO 14
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: DNA primer

<400> SEQUENCE: 14

caccagctct gtctcagag 20

<210> SEQ ID NO 15
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: enzyme substrate

<400> SEQUENCE: 15

Lys Lys Leu Asn Arg Thr Leu Ser Phe Ala Glu Pro Gly
1 5 10

<210> SEQ ID NO 16
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 16

agcgagagat tgccatcttg a 21

<210> SEQ ID NO 17
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 17

gccagagaac ctgctgttgg a 21

<210> SEQ ID NO 18
<211> LENGTH: 3117
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

-continued

<400> SEQUENCE: 18

tggtcggctc agctgcacgg ctccggtcgg ctccggtcgg ctccggtcgg cgcccgctga	60
cgggcgtgcg ctggggggcg ggggcgcggg gcgcgggcct cggcggcggc ggccggcgcg	120
gcggcggaag ccagggtgcc ccgcccgcgc tgctctctcg acgaggcgga ggcgtagcgc	180
cgggccaggc ctccgactgc cgcgtcggag tggacgcggg gggcggcggc gcgggcggac	240
gcgggcggcg cgaagcagcg gggcccgcg gggcgcccg gccgggtcgg cgcggacggc	300
actcggcgga cgcggcgga cgcgtggcg cccctccctg cccgcgcgc cgggcgcgc	360
tggccggcgc tgggccccag agcgatgaca tcgacgggga aggacggcgg cgcgcagcac	420
gcgcagtatg ttggggcccta ccggctggag aagacgctgg gcaaggggca gacaggtctg	480
gtgaagctgg gggttcactg cgtcacctgc cagaagggtg ccatcaagat cgtcaaccgt	540
gagaagctca gcgagtcggt gctgatgaag gtggagcggg agatcgcgat cctgaagctc	600
attgagcacc cccacgtcct aaagctgcac gacgtttatg aaaaacaaaa atatttgtac	660
ctggtgctag aacacgtgtc aggtggtgag ctcttcgact acctggtgaa gaaggggagg	720
ctgacgccta aggaggtcgc gaagtcttc cggcagatca tctctgcgct ggaactctgc	780
cacagccact ccatatgcc aagggatctg aaacctgaaa acctcctgct ggacgagaag	840
aacaacatcc gcatcgaga ctttggcatg gcgtccctgc aggttggcga cagcctgttg	900
gagaccagct gtgggtcccc ccactacgcc tgcgccgagg tgatccgggg ggagaagtat	960
gacggccgga aggcggacgt gtggagctgc ggcgtcatcc tgctgcctt gctggtgggg	1020
gctctgccct tcgacgatga caacttgca cagctgctgg agaaggtaa gcggggcgtg	1080
ttccacatgc cgcactttat cccgccgcac tgccagagtc tgctacgggg catgagcgag	1140
gtggacgcgc cagccgcct cagctagag cacattcaga aacacatatg gtatataggg	1200
ggcaagaatg agcccgaacc agagcagccc attcctcgca aggtgcagat ccgctcgctg	1260
cccagcctgg aggacatcga ccccgacgtg ctggacagca tgcaactact gggctgcttc	1320
cgagaccgca acaagctgct gcaggacctg ctgtccgagg aggagaacca ggagaagtatg	1380
atttacttcc tctcctgga ccggaagaa aggtaccga gccaggagga tgaggacctg	1440
ccccccgga acgagataga cctcccccgg aagcgtgtgg actccccgat gctgaaccgg	1500
cacggcaagc ggccggcaga acgcaaatcc atggagggtgc tcagcgtgac ggacggcggc	1560
tccccggtgc ctgcgcggcg ggccattgag atggcccagc acggccagag gtctcggtcc	1620
atcagcggtg cctcctcagg cctttccacc agccactca gcagcccccg ggtgacccct	1680
cacccctcac caaggggcag tcccctcccc accccaagg ggacacctgt ccacacgcca	1740
aaggagagcc cggctggcac gcccaacccc acgcccccg ccagccccag cgtcgagggg	1800
gtgccctgga gggcgcggt caactccatc aagaacagct ttctgggctc acccgccttc	1860
caccgcccga aactgcaagt tccgacgcgc gaggagatgt ccaacctgac accagagtcg	1920
tcccagagc tggcgaagaa gtctcggttt gggaacttca tcagcctgga gaaggaggag	1980
cagatcttcg tggatcatca agacaaacct ctgagctcca tcaaggctga categtgac	2040
gccttctgt cgattccag tctcagccac agcgtcatct cccaaacgag cttccggggc	2100
gagtacaagg ccacgggggg gccagccgtg ttccagaagc cggtaagtt ccaggttgat	2160
atcacctaca cggagggtgg ggaggcgcag aaggagaacg gcattctact cgtcaccttc	2220

-continued

```

acctgtctct caggccccag ccgtcgcttc aagagggtgg tggagaccat ccaggccccag 2280
ctgctgagca cacacgaccc gcctgcggcc cagcacttgt cagacaccac taactgtatg 2340
gaaatgatga cggggcggtt ttccaaatgt ggaattatcc cgaaaagtta acatgtcacc 2400
tccacgaggc catcctctgt gaccgaaggc agctgtgcg gacccgcctt cctcctgcctc 2460
ctgctgttgc tgcggggcag tgaggcccag cccagcgccc cgtccacccc gcggcagctc 2520
ctcgccctcag ctccgcacgg cccgtgggag gaaggccagg ctcgggggag cctcctccag 2580
cccgcccgac ccggactccc ggtcacctga cccctcagca agaacagcct gcctgttgge 2640
cttctggggc caggaccccc ggtgggcaac gtagccacag gaacaggccc cgtccaccgc 2700
ctccacgccc cacttggagg cctcctgcag gccctgccc cgcctccctg gccgcgccgc 2760
ctccgtgtag tcttgccctc ctccagctgc ctcccgctct ctgctctcac ccgcgcctcc 2820
cttgccctcat ctggggaggc tgtgggctct ggcgctctc tctggctgag gtggaacag 2880
agacaccctg cggcaccaga gccttcccag caggccaggc cgctgggctg ggatcagtgt 2940
tatttatttg ccgttttcca atttatggat tctccgcacc tctgttcagg gaaggcgccg 3000
ggccacatcc cctgccgtct cgctgtctca ggcagtgggg gggtggggc cagggcgccc 3060
tctgaggaca gagctggtgg ggcgcggggg ggctggcgag ctactgtaaa ctttaaa 3117

```

<210> SEQ ID NO 19

<211> LENGTH: 668

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 19

```

Met Thr Ser Thr Gly Lys Asp Gly Gly Ala Gln His Ala Gln Tyr Val
1      5      10      15
Gly Pro Tyr Arg Leu Glu Lys Thr Leu Gly Lys Gly Gln Thr Gly Leu
20     25     30
Val Lys Leu Gly Val His Cys Val Thr Cys Gln Lys Val Ala Ile Lys
35     40     45
Ile Val Asn Arg Glu Lys Leu Ser Glu Ser Val Leu Met Lys Val Glu
50     55     60
Arg Glu Ile Ala Ile Leu Lys Leu Ile Glu His Pro His Val Leu Lys
65     70     75     80
Leu His Asp Val Tyr Glu Asn Lys Lys Tyr Leu Tyr Leu Val Leu Glu
85     90     95
His Val Ser Gly Gly Glu Leu Phe Asp Tyr Leu Val Lys Lys Gly Arg
100    105    110
Leu Thr Pro Lys Glu Ala Arg Lys Phe Phe Arg Gln Ile Ile Ser Ala
115    120    125
Leu Asp Phe Cys His Ser His Ser Ile Cys His Arg Asp Leu Lys Pro
130    135    140
Glu Asn Leu Leu Leu Asp Glu Lys Asn Asn Ile Arg Ile Ala Asp Phe
145    150    155    160
Gly Met Ala Ser Leu Gln Val Gly Asp Ser Leu Leu Glu Thr Ser Cys
165    170    175
Gly Ser Pro His Tyr Ala Cys Pro Glu Val Ile Arg Gly Glu Lys Tyr
180    185    190
Asp Gly Arg Lys Ala Asp Val Trp Ser Cys Gly Val Ile Leu Phe Ala

```


-continued

195					200					205					
Leu	Leu	Val	Gly	Ala	Leu	Pro	Phe	Asp	Asp	Asp	Asn	Leu	Arg	Gln	Leu
210					215						220				
Leu	Glu	Lys	Val	Lys	Arg	Gly	Val	Phe	His	Met	Pro	His	Phe	Ile	Pro
225					230					235					240
Pro	Asp	Cys	Gln	Ser	Leu	Leu	Arg	Gly	Met	Ser	Glu	Val	Asp	Ala	Ala
				245					250					255	
Arg	Arg	Leu	Thr	Leu	Glu	His	Ile	Gln	Lys	His	Ile	Trp	Tyr	Ile	Gly
			260					265					270		
Gly	Lys	Asn	Glu	Pro	Glu	Pro	Glu	Gln	Pro	Ile	Pro	Arg	Lys	Val	Gln
		275					280					285			
Ile	Arg	Ser	Leu	Pro	Ser	Leu	Glu	Asp	Ile	Asp	Pro	Asp	Val	Leu	Asp
	290					295					300				
Ser	Met	His	Ser	Leu	Gly	Cys	Phe	Arg	Asp	Arg	Asn	Lys	Leu	Leu	Gln
305					310					315					320
Asp	Leu	Leu	Ser	Glu	Glu	Glu	Asn	Gln	Glu	Lys	Met	Ile	Tyr	Phe	Leu
				325					330					335	
Leu	Leu	Asp	Arg	Lys	Glu	Arg	Tyr	Pro	Ser	Gln	Glu	Asp	Glu	Asp	Leu
			340					345					350		
Pro	Pro	Arg	Asn	Glu	Ile	Asp	Pro	Pro	Arg	Lys	Arg	Val	Asp	Ser	Pro
		355					360					365			
Met	Leu	Asn	Arg	His	Gly	Lys	Arg	Arg	Pro	Glu	Arg	Lys	Ser	Met	Glu
	370					375					380				
Val	Leu	Ser	Val	Thr	Asp	Gly	Gly	Ser	Pro	Val	Pro	Ala	Arg	Arg	Ala
385					390					395					400
Ile	Glu	Met	Ala	Gln	His	Gly	Gln	Arg	Ser	Arg	Ser	Ile	Ser	Gly	Ala
			405					410						415	
Ser	Ser	Gly	Leu	Ser	Thr	Ser	Pro	Leu	Ser	Ser	Pro	Arg	Val	Thr	Pro
			420					425					430		
His	Pro	Ser	Pro	Arg	Gly	Ser	Pro	Leu	Pro	Thr	Pro	Lys	Gly	Thr	Pro
		435					440					445			
Val	His	Thr	Pro	Lys	Glu	Ser	Pro	Ala	Gly	Thr	Pro	Asn	Pro	Thr	Pro
	450					455					460				
Pro	Ser	Ser	Pro	Ser	Val	Gly	Gly	Val	Pro	Trp	Arg	Ala	Arg	Leu	Asn
465				470						475					480
Ser	Ile	Lys	Asn	Ser	Phe	Leu	Gly	Ser	Pro	Arg	Phe	His	Arg	Arg	Lys
			485						490					495	
Leu	Gln	Val	Pro	Thr	Pro	Glu	Glu	Met	Ser	Asn	Leu	Thr	Pro	Glu	Ser
			500					505					510		
Ser	Pro	Glu	Leu	Ala	Lys	Lys	Ser	Trp	Phe	Gly	Asn	Phe	Ile	Ser	Leu
		515					520					525			
Glu	Lys	Glu	Glu	Gln	Ile	Phe	Val	Val	Ile	Lys	Asp	Lys	Pro	Leu	Ser
	530					535					540				
Ser	Ile	Lys	Ala	Asp	Ile	Val	His	Ala	Phe	Leu	Ser	Ile	Pro	Ser	Leu
545				550						555					560
Ser	His	Ser	Val	Ile	Ser	Gln	Thr	Ser	Phe	Arg	Ala	Glu	Tyr	Lys	Ala
			565						570					575	
Thr	Gly	Gly	Pro	Ala	Val	Phe	Gln	Lys	Pro	Val	Lys	Phe	Gln	Val	Asp
			580					585					590		
Ile	Thr	Tyr	Thr	Glu	Gly	Gly	Glu	Ala	Gln	Lys	Glu	Asn	Gly	Ile	Tyr
	595						600					605			

-continued

Ser	Val	Thr	Phe	Thr	Leu	Leu	Ser	Gly	Pro	Ser	Arg	Arg	Phe	Lys	Arg
610						615					620				
Val	Val	Glu	Thr	Ile	Gln	Ala	Gln	Leu	Leu	Ser	Thr	His	Asp	Pro	Pro
625					630					635				640	
Ala	Ala	Gln	His	Leu	Ser	Asp	Thr	Thr	Asn	Cys	Met	Glu	Met	Met	Thr
				645					650					655	
Gly	Arg	Leu	Ser	Lys	Cys	Gly	Ile	Ile	Pro	Lys	Ser				
			660				665								

1. A method of detecting type 1 diabetes in a patient, comprising:

reacting a patient sample with a PBK1 protein or a fragment thereof under conditions that promote antibody-antigen binding; and
detecting the presence of an autoantibody in said sample.

2. The method of claim 1 wherein the PBK1 protein is immobilized on a solid support.

3. The method of claim 1 wherein the patient sample is selected from the group consisting of: blood, serum, plasma, and a biopsy tissue.

4. The method of claim 1 wherein the detecting of the autoantibody comprises reacting the autoantibody with an antibody having a detectable label.

5. A mammalian pancreas-derived cell comprising a recombinant nucleic acid encoding a PBK1 protein.

6. The mammalian pancreas-derived cell of claim 5 wherein the cell is a cell of a mammalian pancreas-derived cell line.

7. The pancreas-derived cell of claim 5 wherein the cell is a Min6 cell transfected with a recombinant nucleic acid encoding a PBK1 protein.

8. A method of identifying a PBK1 modulator, comprising one or more of:

a) contacting a PBK1 protein with a test agent under conditions that promote kinase activity of said PBK1 protein, and detecting an increase in the kinase activity; and

b) contacting a cell that expresses a PBK1 protein with a test agent under conditions that promote glucose-stimulated insulin secretion from said cell, and detecting an increase in the glucose-stimulated insulin secretion from the cell; wherein

said increase in a) or b) each indicates that the test agent is a PBK1 modulator.

9. The method of claim 8 further comprising determining that the increase in the glucose-stimulated insulin secretion comprises potentiation of secretagogue-stimulated insulin secretion from a cell that expresses a PBK1 protein.

10. The method of claim 8 wherein the cell is a mammalian pancreas-derived cell.

11. The method of claim 8 wherein the cell is a MIN6 cell.

12. The method of claim 8 wherein the cell contains a recombinant nucleic acid encoding a PBK1 protein.

13. A method of screening for an agent that treats a metabolic disease, said method comprising one or more of:

a) contacting a PBK1 protein with a test agent under conditions that promote binding of said test agent to said PBK1 protein, and detecting binding of said test agent to said PBK1 protein; and

b) contacting a PBK1 protein with a test agent under conditions that promote kinase activity of said PBK1 protein, and detecting an increase in the kinase activity; and

c) contacting a cell that expresses a PBK1 protein with a test agent under conditions that promote glucose-stimulated insulin secretion from said cell, and detecting an increase in the glucose-stimulated insulin secretion from the cell; wherein

said disorder is selected from diabetes, type 2 diabetes, obesity, and diabetic retinopathy.

14. The method of claim 13, further comprising designating said test agent as a compound that treats said disease.

15. The method of claim 13, further comprising designating said test agent as a compound that treats said disease.

16. The method of claim 13, further comprising designating said test agent as a compound that treats type 2 diabetes.

17. The method of claim 13, wherein said PBK1 protein is selected from a protein having a polypeptide sequence that has at least 73%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the protein having a polypeptide sequence set forth in SEQ ID NO: 2.

18. The method of claim 17, wherein said PBK1 protein is selected from a protein having a polypeptide sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 6.

19. The method of claim 13 wherein a) is performed prior to c).

20. The method of claim 13 wherein b) is performed prior to c).

21. The method of claim 13 wherein a) is performed prior to b), and b) is performed prior to c).

22. The method of claim 13 further comprising determining that the increase in the glucose-stimulated insulin secretion comprises potentiation of secretagogue-stimulated insulin secretion from a cell that expresses a PBK1 protein.

23. The method of claim 13 wherein the cell is a mammalian pancreas-derived cell.

24. The method of claim 13 wherein the cell is a MIN6 cell.

25. The method of claim 13 wherein the cell contains a recombinant nucleic acid encoding a PBK1 protein.

26. A method for stimulating cell differentiation and/or regeneration in a pancreatic beta cell comprising delivering PBK-1 DNA to said cell.

27. The method of claim 26 wherein said DNA is operably linked to a promoter that drives expression of said DNA in said cell.

28. A method for in vivo screening for an agent that treats diabetes, said method comprising:

a) subjecting a mammal comprising a PBK1 knockout genome to a diet that promotes diabetes;

b) treating said mammal with a test agent;

c) determining blood glucose level of said mammal; and

d) determining whether said mammal is glucose tolerant.

* * * * *

专利名称(译)	与PBK1有关的方法和组合物		
公开(公告)号	US20100146642A1	公开(公告)日	2010-06-10
申请号	US12/154296	申请日	2008-05-22
申请(专利权)人(译)	宾夕法尼亚州立大学		
当前申请(专利权)人(译)	宾州州立大学研究基金会		
[标]发明人	SHI YUGUANG YE GUANGMING		
发明人	SHI, YUGUANG YE, GUANGMING		
IPC分类号	A61K49/00 G01N33/567 C12N5/071 G01N33/53 C12N9/12 A61P3/10		
CPC分类号	C12Q1/485 C12Q1/6883 G01N33/507 G01N33/5088 C12Q2600/158 G01N2800/042 C12Q2600/136 C12Q2600/156 G01N33/564		
优先权	60/939462 2007-05-22 US		
其他公开文献	US8163505		
外部链接	Espacenet USPTO		

摘要(译)

本发明涉及包含和利用PBK1蛋白和DNA的方法的组合物，包括检测1型糖尿病的方法；哺乳动物胰腺来源的细胞，其包含编码PBK1蛋白的重组核酸；一种鉴定PBK1调节剂的方法；用于治疗受试者的2型糖尿病的药物组合物；一种筛选治疗代谢疾病的药剂的方法；将PI3K-1 DNA递送至受试者以刺激胰腺β细胞分化和/或再生；一种刺激胰腺β细胞中细胞分化和/或再生的方法；使用具有靶向缺失或过表达PI3K-1基因的转基因小鼠来测试PI3K-1调节剂化合物的功效和特异性。

